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Abstract 
 
Farber disease, also known as Farber's lipogranulomatosis (FD, MIM 228000), is a 
rare autosomal recessive disease caused by mutations in the ASAH1 gene. This gene 
codes for acid ceramidase (EC 3.5.1.23), a lysosomal heterodimeric enzyme that is 
responsible for the hydrolysis of ceramide in sphingosine and fatty acids. FD is, therefore, 
characterized by the accumulation of ceramide in various cell types. The disease is 
clinically heterogeneous and 7 subtypes are presently known. Typical symptoms include 
the unique triad of subcutaneous nodules, painful and progressively deformed joints, and 
hoarseness by laryngeal involvement. Although 80 patients with the diagnosis of FD are 
referred in the literature, the genotype was characterized thus far in only 20 patients 
leading to the identification of 23 mutations in the ASAH1 gene, mostly missense 
mutations. Comparing with other lysosomal diseases few causative mutations of FD are 
known, and for the vast majority of them the molecular mechanism is unclear, thus 
hampering the establishment of genotype-phenotype correlations. Moreover, the 
correlation between the clinical phenotype and either the residual acid ceramidase 
enzymatic activity or the level of ceramide storage is still a controversial issue.  
The aim of this thesis was to provide novel insights towards a better understanding of 
the disease molecular pathogenesis through the investigation of genetic and biochemical 
basis of the most severe clinical manifestation of acid ceramidase deficiency ever 
described. 
 In this study, the genotype of a neonate FD patient with non-immunological hydrops 
fetalis was elucidated. Direct sequencing of ASAH1 genomic DNA revealed a causative 
heterozygous mutation in the donor splice site consensus sequence of intron 11, 
g.24491A>G (c.917+4A>G), that resulted in the absence of detectable mRNA. 
Subsequent analysis of ASAH1 mRNA showed total skipping of exons 3 to 5. Long-range 
PCR and sequencing led to the identification of a gross deletion, the first one reported in 
the ASAH1 gene, g.8728_18197del (c.126-3941_382+1358del) predicting the synthesis of 
a truncated polypeptide, p.Tyr42_Leu127delinsArgfs*10. Accordingly, no molecular forms 
corresponding to precursor or proteolytically processed mature protein were observed. 
Molecular findings in the non-consanguineous parents confirmed the compound 
heterozygous ASAH1 genotype identified in the patient. The identification of two 
heterozygous loss-of-function mutations provided experimental evidence for the absence 
of any functionally active acid ceramidase in patient’s fibroblasts, underscoring the 
severity of the clinical phenotype. This data also suggests screening for gross deletions in 
 x 
 
other patients in whom the mutation present in the second allele had not yet been 
identified to elucidate further its overall contribution for the molecular pathogenesis of this 
devastating disease. 
 As data from molecular studies support the existence of a deep blockage of the last 
step of the sphingolipid degradation pathway in patient’s cells, the intracellular level of two 
structurally close and metabolically linked shingolipid molecules, ceramide and 
sphingomyelin, was investigated. The total level of sphingomyelin vs. ceramide was found 
significantly decreased in FD cells, but an analogous disproportion, i.e. a significant 
increase, was not seen in Niemann Pick-type B cells that are characterized by the 
accumulation of sphingomyelin due to the deficient enzymatic activity of acid 
sphingomyelinase. This observation suggests that the imbalance of total sphingomyelin to 
total ceramide observed in FD fibroblasts is likely to be due not only to the abnormally 
high level of ceramide but also to a slightly decreased level of sphingomyelin.  The steady 
state cell level of these metabolites results from a complex network of enzymatic reactions 
catalysed by several ceramidases and sphingomyelinases. If acid sphingomyelinase, 
whose enzymatic activity was found particularly decreased in fibroblasts of the neonatal 
FD patient, represents a disease biomarker is an issue that warrants further investigation. 
Altogether, data here reported suggest that secondary imbalances such as the residual 
acid sphingomyelinase enzymatic activity and the cellular content and distribution of 
sphingolipids might have clinical relevance and also strengthen the hypothesis of an in 
vivo interaction between acid ceramidase and acid sphingomyelinase.  
 Overall, the data described in this thesis made two contributions in this particular field 
of the scientific knowledge: detailed analysis on the biological consequences of novel 
ASAH1 mutations provided a better understanding of the primary defect of the neonatal 
FD; enzymatic and biochemical sphingolipid data analysis revealed secondary defects 
whose implication for the disease pathophysiology must continue to be investigated in the 
future. 
Key-words: Lysosomal disease, Farber disease, Acid ceramidase, ASAH1 gene, Gross 
deletion, Splicing mutation, Ceramide, Sphingomyelin. 
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Resumo 
 
A doença de Farber (Lipogranulomatose de Farber, MIM 228000) é uma doença rara, 
de transmissão autossómica recessiva, causada por mutações no gene ASAH1. Este 
gene codifica para a ceramidase ácida (EC 3.5.1.23) que é uma enzima heterodimérica 
responsável pela hidrólise da ceramida em esfingosina e ácido gordo. A doença de 
Farber é, por isso, caracterizada pela acumulação lisossomal de ceramida em vários 
tipos de células. Esta patologia é clinicamente heterogénea, estando descritos 7 subtipos. 
Os sintomas clínicos típicos incluem a presença de nódulos subcutâneos, a deformação 
progressiva das articulações e rouquidão causadas por alterações na laringe. Dos 80 
doentes de Farber referidos na literatura, apenas 20 foram caracterizados 
genotipicamente o que originou a identificação de 23 mutações no gene ASAH1, a 
maioria das quais mutações missense. Comparativamente com outras doenças 
lisossomais, o número de mutações causais é reduzido e para a maioria delas o 
mecanismo molecular não está bem estabelecido dificultando, assim, o estabelecimento 
de correlações genótipo-fenótipo. Além disso, a correlação entre o fenótipo clínico e a 
atividade enzimática residual da ceramidase ácida ou os níveis de acumulação de 
ceramida é ainda uma questão controversa. 
Este projeto foi desenvolvido com o objetivo de promover o conhecimento sobre a 
patogénese molecular desta doença através da investigação das bases genéticas e 
bioquímicas da forma clinica mais grave da deficiência em ceramidase ácida até hoje 
descrita.  
Neste trabalho, o genótipo de um doente de Farber com a forma neonatal e 
apresentando hidropsia fetal não imune foi elucidado. A análise do DNA genómico do 
gene ASAH1 revelou a presença em heterozigotia da mutação g.24491A>G 
(c.917+4A>G), no local doador de splicing do intão 11, resultando na ausência de mRNA 
detectável. A análise subsequente do mRNA/ASAH1 revelou a excisão da totalidade dos 
exões 3 a 5. A conjugação das técnicas Longe-range PCR e sequenciação permitiram a 
identificação da primeira grande deleção no gene ASAH1, 8728_18197del (c.126-
3941_382+1358del), sugerindo a síntese de um polipéptido truncado, 
p.Tyr42_Leu127delinsArgfs*10. Estudos ao nível da proteína revelaram ausência das 
formas moleculares precursora ou madura da enzima. O estudo molecular dos pais não 
consanguíneos confirmou o genótipo heterozigótico do doente. Assim, a identificação e 
caracterização destas duas mutações heterozigóticas evidenciou a inexistência de 
ceramidase ácida funcional em fibroblastos deste doente corroborando, assim, a 
 xii 
 
severidade do fenótipo clínico. Estes resultados também demonstram a importância do 
rastreio de grandes deleções em doentes compostos heterozigóticos e cuja mutação no 
segundo alelo ainda não tenha sido identificada, já que este tipo de mutação poderá estar 
implicado na patogénese molecular da doença.  
Tendo em conta que os resultados obtidos sugerem um bloqueio profundo do último 
passo da degradação dos esfingolípidos nas células do doente com a forma neonatal de 
Farber, os níveis intracelulares de duas moléculas esfingolípicas, estrutural e 
metabolicamente relacionadas, a ceramida e a esfingomielina, foram investigados. Em 
fibroblastos do doente foi observada uma redução significativa do nível total de 
esfingomielina vs. ceramida em relação a células controlo, mas uma desproporção 
análoga, isto é, um aumento significativo, não foi observado em células de doentes 
Niemann Pick-tipo B (células caracterizadas pela acumulação de esfingomielina devido à 
deficiente atividade enzimática da esfingomielinase ácida). Esta observação sugere que o 
desequilíbrio entre os níveis de esfingomielina total e ceramida total obtidos em 
fibroblastos do doente deverá resultar não só de um nível anormalmente elevado de 
ceramida mas também de um nível ligeiramente diminuído de esfingomielina. Na células, 
o nível de equilíbrio destes metabolitos resulta de uma rede complexa de reações 
enzimáticas catalisadas por diversas ceramidases e esfingomielinases. Uma vez que nos 
fibroblastos do doente de Farber foi observada uma redução significativa da atividade 
enzimática da esfingomielinase ácida, a possibilidade desta enzima representar um 
biomarcador da doença é uma questão que deverá ser investigada no futuro. 
Globalmente, os resultados obtidos no âmbito do presente trabalho sugerem que 
alterações secundárias, tais como a atividade enzimática residual da esfingomielinase 
ácida, ou o conteúdo e distribuição celulares dos esfingolípidos, poderão ter relevância 
clínica e, adicionalmente, apoiam a hipótese de uma interação in vivo entre a ceramidase 
ácida e a esfingomielinase ácida. 
Em suma, os resultados descritos nesta tese proporcionaram duas contribuições 
neste domínio específico do conhecimento científico: a análise detalhada sobre as 
consequências biológicas das mutações novas identificadas no gene ASAH1 
proporcionou uma melhor compreensão do defeito primário da forma neonatal da doença 
de Farber; a análise enzimática e bioquímica dos esfingolípidos revelou defeitos 
secundários cuja implicação para a fisiopatologia da doença deve continuar a ser 
investigada no futuro. 
Palavras-chave: Doenças lisossomais, Doença de Farber, Ceramidase ácida, Gene 
ASAH1, Grande deleção, Mutação de splicing, Ceramida e Esfingomielina. 
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I.1. LYSOSOME 
In 1949, Christian de Duve, then chairman of the Laboratory of Physiological 
Chemistry at the University of Louvain in Belgium, was studying how insulin acted on liver 
cells. He wanted to determine the location of glucose-6-phosphatase, an important 
enzyme in regulating blood sugar levels. He and his group obtained cellular extracts by 
blending rat liver fragments in distilled water and centrifuging the mixture at high speeds. 
They observed high phosphatase activity in the extracts. However, when they tried to 
purify the enzyme from cellular extracts, they could precipitate the enzyme, but they could 
not redissolve it. Instead of using cellular extracts, they decided to use a more gentle 
technique that fractionated the cells with differential centrifugation, separating different 
components of cells based on their sizes and densities. The researchers ruptured the rat 
liver cells and then fractionated the samples in a sucrose medium. They succeeded in 
detecting the enzyme's activity in what is known as the microsomal fraction of the cell.  
As control for their experiments, the scientists were using the enzyme acid 
phosphatase. To their surprise, the acid phosphatase activity after differential 
centrifugation was only 10% of the expected enzymatic activity (i.e., the activity they 
obtained in their previous experiments using cellular extracts). One day, by chance, a 
scientist purified some cell fractions and then left them in the fridge. Five days later, after 
returning to measure the enzymatic activity of the fractions, they observed the enzymatic 
activity levels they were looking for. To ensure there was no mistake, they repeated the 
experiment a number of times. Each time, the results were the same: if they measured the 
enzymatic activity using fresh samples, then the activity was only 10% of the activity 
obtained when they let the samples rest for five days in the fridge. To explain these 
results, they hypothesized that a membrane-like barrier limited the accessibility of the 
enzyme to its substrate. Letting the samples rest for a few days gave the enzymes time to 
diffuse. They described the membrane-like barrier as a "saclike structure surrounded by a 
membrane and containing acid phosphatase". By 1955, additional hydrolases were 
discovered in these saclike structures (de Duve et al., 1955), suggesting that they were a 
new type of organelle with a lytic function. De Duve named these new organelles 
"lysosomes" to reflect their lytic nature. That same year, an experienced microscopist, 
Novikoff from University of Vermont, was able to obtain the first electron micrographs of 
the new organelle from samples of partially purified lysosomes. Using a staining method 
for acid phosphatase, de Duve and Novikoff confirmed its location in the lysosome using 
light and electron microscopy studies (Essner and Novikoff, 1961), but their functional 
Introduction 
 4 
significance was only understood later after biochemical studies (rev. in De Duve and 
Wattiaux, 1966).  
For long time, we know that lysosomes contain hydrolases that are capable of 
digesting all kinds of macromolecules. Christian de Duve, Albert Claude, and George 
Palade were recognized for their work detailing the functions of the lysosome, when they 
were awarded the Nobel Prize in Physiology or Medicine in 1974. Nowadays, new roles of 
lysosomes are emerging and their implication in health and disease is next discussed. 
 
I.1.1. Ultrastructure and function 
Lysosomes are found in almost all eukaryotic cells. They are intracellular organelles 
of about 0.5 m diameter, enclosed by a membrane, and considered for a long time the 
organelle involved in the degradation and recycling of cellular waste (rev. in Bärrett and 
Heath, 1977). 
Various methods have been used to purify lysosomes and analyze their proteome. 
Some of these approaches are based on subcellular fractionations or on the specific 
feature of soluble lysosomal proteins, e.g. the presence of the mannose-6-phosphate 
(M6P) modification of their carbohydrate chains. On the basis of present data about 110 
lysosome-resident proteins have been identified: ~65 are matrix proteins and ~45 are 
lysosomal membrane proteins (LMPs). The most abundant LMPs are lysosome 
associated membrane proteins 1 and 2 (LAMP1 and LAMP2) and lysosomal integral 
membrane protein 2 (LIMP2, also known as SCARB2) and the tetraspanin CD63 (rev. in 
Schröder et al., 2010). 
The soluble hydrolases, which are active at acidic pH, include proteases, nucleases, 
glycosidases, lipases, phosphatases and sulfatases that target specific substrates for 
degradation into their structural monomers (amino acids, fatty acids, simple sugars and 
nucleotides) and reutilization by the cell. Their collective action is responsible for the total 
catabolic ability of the lysosome. 
 Like all other intracellular organelles, the lysosome also has a unique surrounding 
membrane, with an H+ pump (Figure 1.1) that uses the energy of ATP hydrolysis to 
translocate H+ into the lysosome, thereby maintaining the lumen at its acidic pH (5.0), 
necessary for optimal activity of lysosomal enzymes. Most of the LMPs are unusually 
highly glycosylated which helps to protect them from the luminal lysosomal proteases. In 
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this way, the contents of the cytosol are doubly protected against attack by the cell´s own 
digestive system. Even if the lysosomal membrane leaks out, digestive enzymes can do 
little damage at the cytosolic pH of about 7.2. Besides the lysosomal membrane protection 
function and the transport of metabolites into and out of lysosomes, LMPs are also 
involved in fusion events of the lysosomal membrane with other cell structures, such as 
late endosomes (LE), autophagosomes and the plasma membrane (PM) (rev. in 
Eskelinen et al., 2003). 
  
 
Figure 1.1. Major components of lysosomal membrane. The multi-subunit v-type H+ 
ATPase mediates transport of protons into the lysosomal lumen and the chloride channel ClC-7 
drives chloride anion transport into the lysosome using the proton gradient. CD63, human cluster of 
differentiation 63; DIRC2, disrupted in renal carcinoma 2; LAMP, lysosome-associated membrane 
proteins; SCARB2, human scavenger receptor class B, member 2. Figure taken from rev. in 
Schwake et al., 2013.  
 
On the basis of current knowledge, three general main functions can be attributed to 
lysosomes: degradation, secretion and signaling.  
 
Cytosol
Lysosome
PM
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As a catabolic cell compartment, hydrolases ensure the degradation of a wide variety 
of intracellular and extracellular molecules that reach lysosomes using specific cell routes. 
 Lysosomal secretion occurs through a process called lysosomal exocytosis. In this 
process, lysosomes fuse with the PM through a Ca2+-regulated mechanism (rev. in 
Micaroni, 2012). Lysosomal exocytosis is transcriptionally regulated by the transcription 
factor EB (TFEB) which induces both the docking and fusion of lysosomes with the PM by 
modulating the expression of specific genes (Medina et al., 2011). Lysosomal exocytosis 
has been implicatef in several physiological processes, such as microorganism defense 
mechanism, bone resorption by osteoclasts, melanocyte function in pigmentation, platelet 
function in coagulation, hydrolase release by spermatozoa during fertilization and PM 
repair (rev. in Settembre et al., 2013). 
Lysosomal signaling refers to its role in nutrient sensing and, subsequently, in a 
signaling pathway(s) that is involved in cell metabolism and growth, keeping the balance 
between biosynthetic and catabolic cell states (rev. Zoncu et al., 2011). This function 
involves the kinase complex mammalian target of rapamycin complex (mTORC1). Growth 
factors, hormones, amino acids, glucose (Glc), oxygen and stress are the major activators 
of mTORC1, which in turn positively regulates lipid biosynthesis and ATP production (rev. 
in Laplante and Sabatini, 2012). The recent observation that the level of mTORC1 exerts 
its activity on the lysosomal surface (Sancak et al., 2010) and that the amino acids must 
accumulate in the lysosomal lumen in order for mTORC1 to bind and become activated 
(rev. Zoncu et al., 2011), support the idea that mTORC1 activity is dependent on 
lysosome.  
 In spite of the progresses described above, little is known about how lysosomal 
function varies in different cells, tissues, life stages and individuals, as well as under 
distinct physiological conditions. However, to fulfill these varied roles, lysosomes must be 
present at different levels in different tissues and cell types and their makeup within these 
different tissues diversify. The complexity of this organelle is reflected by its highly 
polymorphic ultrastructure, its spatial and functional affinity with endocytic compartments 
and its temporal continuation with the endoplasmic reticulum and secretory vesicles. 
Therefore, the biogenesis of this organelle is a complex process requiring the coordinated 
expression of many soluble and membrane proteins. 
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I.1.2. Biogenesis 
Lysosome biogenesis involves the integration of components of the biosynthetic, 
exocytic and endocytic pathways of the cell.  
 
I.1.2.1. Biosynthetic pathway  
Lysosomal proteins are mostly glycoproteins consisting of mannose-rich 
oligosaccharides. The biosynthesis occurs on ribosomes associated with the rough 
endoplasmic reticulum (RER), with subsequent translocation of the polypeptides into the 
lumen of RER, where specific asparagine residues (Asn-X-Ser/Thr) are N-glycosylated. 
Two pathways are known to target proteins to lysosomes: the M6P dependent pathway 
and the M6P independent pathway (rev. in Kornfeld and Mellman, 1989).  
During its vectorial transport through the Golgi complex (GC), glycoproteins are 
proteolytic and oligosaccharide processed. Mannose-rich N-oligosaccharides are 
converted into complex N-oligosaccharides or hybrid structures, and the phosphate group 
is added by the action of the enzymes N-acetylglucosamine-1-phosphodiester -N-
acetylglucosaminidase and uridine diphosphate (UDP)-N-acetylglucosamine-1-
phosphotransferase, with formation of the sorting lysosomal marker M6P. In the trans-GC, 
lysosomal glycoproteins bind to specific membrane receptors, M6P receptors (M6PR): 
cation-independent M6PR and cation-dependent M6PR. These receptors recognize M6P 
residues and are responsible for lysosomal vesicular transport of glycoproteins from the 
trans-GC to the LE. Thus, segregation among the lysosomal protein and protein secretion 
occurs in the trans-GC (rev. in Luzio et al. 2000; rev. in Mullins and Bonifacino, 2001). 
In LE and hybrid structures, decreased pH (5-6) causes the separation between the 
receptor and the lysosomal protein. The lysosomal enzyme is dephosphorylated to 
prevent its return to the GC and the M6PR are included in membrane vesicles which 
transport it back to the GC or to the PM, for reutilization (Figure 1.2). Thus, lysosomes are 
defined not only by the presence of acid hydrolases and integral membrane glycoproteins 
but also by the absence of the two M6PR and recycling cell surface receptors, which 
distinguishes them from endosomes (rev. in Luzio et al. 2000; rev. in Mullins and 
Bonifacino, 2001).  
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Figure 1.2. Sorting and targeting of lysosomal proteins by M6P receptors. Lysosomal 
hydrolase precursors are synthesized in the endoplasmatic reticulim, then modified and sorted in 
the Golgi apparatus. The lysosomal hydrolases are modified by GlcNAc phosphotransferase, which 
adds M6P to these proteins. These modified lysosomal hydrolases are bound by M6P receptors in 
the Golgi apparatus. The receptor-protein complexes are transported in vesicles to the late 
endosomes. Due to the low pH in endosomes, the M6P receptor-protein complexes dissociate. The 
lysosomal hydrolases remain in the endosomes and the endosomes mature into lysosomes. The 
M6P receptors are recycled back to the Golgi apparatus via vesicle transport. GlcNAc, 
acetylglucosamine; M, mannose residue; M6P, mannos-6-phospate; P, phospate. Figure taken 
from rev. in Coutinho et al., 2012.  
 
Although M6PR play a major role in the intracellular transport of newly synthesized 
lysosomal enzymes in mammalian cells, several lines of evidence suggest the existence 
of an alternative mechanism of lysosomal targeting (rev. in Ni et al., 2006). LIMP2 was 
implicated in the delivery of -glucocerebrosidase (GlcCase), the defective enzyme in 
patients with Gaucher disease to the lysosomes (Reczek et al., 2007). Sortilin is a 
multifunctional receptor capable of binding different ligands, including neurotensin (Munck 
et al., 1999), and has been suggested to mediate GC-to-lysosome transport of the 
sphingolipid activator proteins (SAPs) prosaposin and GM2 activator protein (GM2AP, 
Lefrancois et al., 2003; Hassan et al., 2004), acid sphingomyelinase (aSMase, Ni and 
Morales, 2006) and cathepsins D and H (Canuel et al., 2008).  
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I.1.2.2. Exocytic pathway  
The exocytic pathway moves cargo from the endoplasmatic reticulum (ER) through 
the GC to the PM by vesicular transport pathways in a succession of vesicle budding and 
fusion reactions (Figure 1.3). Vesicle coat proteins drive the formation of these vesicles: 
cytoplasmic coat protein (COP) II buds vesicles from ER to cis-GC and clathrin/adaptor 
protein 1 (AP1) is involved in budding from the trans-GC to LE (rev. in Bonifacino and 
Glick, 2004; Lee and Goldberg, 2010). Cargo-packed vesicles (clathrin/AP1 and 
clathrin/AP2) formed at the trans-GC fuse with the PM to deliver PM resident proteins and 
secreted proteins (Tokarev et al., 2009). In addition, resident proteins that move to the 
next compartment have to be retrieved back to the original compartment for maintenance 
of compartment identity. Therefore, for every step of forward transport, there is a 
corresponding retrograde transport step. The two major intersections of this bi-directional 
trafficking are the ER-GC intermediate compartment (ERGIC), which recycles proteins 
back to the ER mediated by COP I, and recycling endosomes, which recycle proteins 
back to the PM or the GC (rev. in Saraste and Goud, 2007).   
 
I.1.2.3. Endocytic pathway  
Endocytosis is a vital process for mammalian cells by which they communicate with 
their environment, internalize nutrients, hormones, or growth factors, or take up 
extracellular fluids and particles. Endocytic mechanisms include phagocytosis, 
macropinocytosis, clathrin-mediated endocytosis or caveolin-mediated endocytosis, 
according to the nature of the cargo. The clathrin/AP2-mediated endocytosis (Figure 1.3.) 
is the best studied one (rev. in Rodemer and Haucke, 2008). 
 The degradative endocytic pathway starts at the PM, with the involvement and fusing 
of the cargo with PM and the formation of endossomal vesicles, and ends in lysosomes. 
Between these two ‘stations’, endocytosed cargo passes through a range of endosomal 
intermediates that are distinguished by their content, molecular composition, morphology 
and pH and by the kinetics by which endocytic tracers reach them (rev. in Sachse et al., 
2002).  
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Figure 1.3. Vesicle coat proteins-mediated exocytic and endocytic pathways. COPII 
(blue) forms vesicles for anterograde transport from the ER to the GC, whereas COPI (red) forms 
vesicles for both intra-GC transport and retrograde transport from the GC to the ER. Clathrin 
(yellow) forms multiple complexes based on its association with different APs. Clathrin that is 
associated with AP1 and AP3 forms vesicles for transport from the trans-GC to the LE 
compartments, and also for transport that emanates from the early endosomal compartments. 
Clathrin that is associated with AP2 forms vesicles from the plasma membrane that transport cargo 
to the early endosomes. AP, adaptor protein; COP, coat protein; GC, Golgi complex; ER, 
endoplasmatic reticulum; LE, late endosome. Figure taken from Bonifacino and Glick, 2004. 
    
The mechanism of transfer of endocytosed material from endosomes to lysosomes 
remained controversial, with several theories being proposed. These included maturation 
(of the endosome into a lysosome), vesicular transport (with vesicles carrying cargo from 
endosomes to lysosomes), kiss-and-run (a continuous cycle of transient contacts or 
‘kisses’ between endosomes and lysosomes, during which material is transferred between 
the organelles and each contact is followed by a dissociation or ‘run’), direct fusion (of the 
endosome to the lysosome to form a hybrid organelle) and fusion–fission (a variation of 
direct fusion and kiss-and-run, in which lysosomes re-form from hybrid organelles as a 
result of fission events) (rev. in Luzio et al., 2003; rev. in Luzio et al., 2007b). Time-lapse 
confocal microscopy experiments have shown that kissing and direct fusion events both 
contribute to the mixing of the contents of endosomes and lysosomes in living cells (Bright 
et al., 2005). Endosomal trafficking and fusion are mediated by specific sets of 
membrane-associated Rab GTPases (rev. in Zerial et al., 2001) and SNARE proteins (rev. 
in Jahn and Scheller, 2006). The fusion of endosomes with lysosomes creates hybrid 
organelles in which the bulk of the endocytosed cargo is degraded. Reformation of 
lysosomes from these hybrid organelles requires retrieval and/or recycling of some 
membrane proteins by vesicular traffic (Bright et al., 2005; Pryor et al., 2005). This view of 
lysosomes as fusogenic organelles is consistent with other data showing that lysosomes 
can also fuse with phagosomes, autophagosomes and the PM under appropriate 
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circumstances (Luzio et al., 2007a, 2007b). Under physiological conditions, 
endolysosomes and autolysosomes are transient organelles. 
The biogenesis and functioning of endosomal and autophagosomal pathways is 
controlled by TFEB, which regulates the expression of 471 genes that constitute the 
CLEAR (coordinated lysosomal expression and regulation) gene network (Sardiello et al., 
2009; Palmieri et al., 2011). Recent work indicates that non-active TFEB is highly 
phosphorylated and associates with LE/lysosomes (Roczniak-Fergunson et al., 2012). 
Autophagy-inducing conditions (e.g., deprivation of Glc or amino acids) result in reduced 
TFEB phosphorylation, leading to its translation into the nucleus (Peña-Llopis and 
Brugarolas, 2011; Peña-Llopis et al., 2011) and transcriptional expression of CLEAR 
genes (Palmieri et al., 2011). Interestingly, TFEB can interact with mTORC1 and 
associated proteins (Settembre et al., 2012; Martina and Puertollano, 2013), suggesting a 
mechanism by which the lysosome regulates its own biogenesis by controlling TFEB 
subcellular localization.  
 
I.2. SPHINGOLIPIDS 
 
I.2.1. Structure and function 
Sphingolipids (SLs) are a complex class of molecules that are found in essentially all 
animals, plants and fungi, and some prokaryotic organisms and viruses. Structurally, SLs 
are amphipathic molecules that have both hydrophobic and hydrophilic properties. They 
consist of a sphingoid long chain base (normally sphingosine (Sph), sphinganine or 
phytosphingosine) to which a fatty acid is attached by an amide bond to carbon 2 
(hydrophobic region) and a headgroup at the primary hydroxyl (hydrophilic region). The 
headgroups range in complexity from a simple H in ceramide (Cer) to complex SLs, 
including sphingomyelin (SM) and glycosphingolipids (GSLs) with a few to dozens of 
sugar residues. Thus, Cer constitute the hydrophobic backbone of all complex SLs (Figure 
1.4.). The fatty acid chain length of Cer can vary from 2 to 28 carbons, but C-16 to C-24 
Cer are the most abundant in mammalian cells (rev. in Merrill et al., 2007). 
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Figure 1.4. Structure of sphingolipids. Ceramide is the simplest SL and the backbone of all 
complex SLs. Note that, for simplicity, only one kind of sphingoid base  (sphingosine in blue),  is 
shown to which only one kind of fatty acid (palmitic acid, in red) is N-acylated. Similarly, only one 
GSL, (with one Glc residue in grey) is shown, but sequential addition of other carbohydrate 
residues results in >500 known GSL structures. Glc, glucose; GSL, glycosphingolipid; SL, 
sphingolipid. Figure adapted from Futerman and Hannun, 2004. 
 
Together with phospholipids and cholesterol, SM and GSLs are characteristic 
components of cellular membranes. They are predominantly found in the PM, and to a 
lesser extent in intracellular membranes (rev. in van Meer and Hoetzl, 2010). Besides 
their structural role, SLs have also been implicated as cell-signaling modulators in a 
variety of vital cellular processes like differentiation, migration, apoptosis, cell proliferation, 
cell cycle arrest, senescence, and inflammation. They are located in multiple intracellular 
organelles, including GC membranes, mitochondria and nucleus, and intracellular vesicles 
(rev. in Dickson, 2008). In some cases, they are organized in small, dynamic aggregates 
within membranes referred to as ‘‘rafts’’ where they can influence the localization and 
functions of transporters and receptors (Hou et al., 2008).  
 
 
Ceramide Sphingomyelin Glucosylceramide
and glycolipids
Fatty acid
Sphingoid base
(sphingosine)
Headgroup
Introduction 
 13
I.2.2. Metabolism and transport 
SLs are synthesized in the ER from non-sphingolipid precursors. Despite the 
structural diversity, their synthesis and degradation are conducted by common anabolic 
and catabolic pathways. The synthesis of Cer, common to all SLs, can occur through 
three major pathways: de novo biosynthesis, SM hydrolysis, and the salvage pathway 
(Figure 1.5.).  
 
I.2.2.1. De novo biosynthesis 
 The de novo biosynthesis of Cer occurs at the cytosolic leaflet of the ER (Hirschberg 
et al., 1993; Michel et al., 1997) and begins with condensation of serine and palmitoyl-
coenzyme A by serine palmitoyltransferase to form 3-ketosphinganine. In the next steps, 
the 3-ketosphinganine is reduced to sphinganine by 3-ketosphinganine reductase 
(Mandon et al., 1992) followed by N-acylated to dihydroceramide by dihydroceramide 
synthase (rev. in Pewzner-Jung and Futerman, 2006). The resultant dihydroCer is 
converted to Cer via insertion of a 4,5-transdouble bond into the sphingoid base backbone 
by dihydroCer desaturases (Michel et al., 1997). Cer is then trafficked to GC via vesicular 
transport, coatomer protein dependent (rev. in Watson and Stephens, 2005) or via the Cer 
transfer protein (CERT) (Hanada et al., 2003) where it is the substrate for the synthesis of 
more complex SLs, including SM and glucosylceramide (GlcCer) which is, then, converted 
into hundreds of complex GSLs. Synthesis of SM in the GC (Futerman et al., 1990; Jeckel 
et al., 1990) is catalyzed by two SM synthases, SMS1 and SMS2 (Voelker and Kennedy, 
1982). Cer is also metabolized to SM in the PM (Malgat et al., 1986; van den Hill et al., 
1985) by the action of SMS2 (Huitema et al., 2004). 
 Most of complex GSLs are synthesized by the stepwise addition of carbohydrate 
molecules. Galactosylceramide (GalCer) and GlcCer, are synthesized using UDP-GlcCer 
glucosyltransferase and UDP-GalCer galactosyltransferase, respectively. Synthesis of 
GalCer occurs in the lumen of the ER whereas GlcCer is thought to be made on the 
cytosolic surface of GC (Sprong et al., 2003). GlcCer is followed by the addition of 
galactose to form Gal1-4Glc1Cer (lactosylceramide, LacCer), which provides the 
branch point for the synthesis of all GSL series: ganglio (galNAc1-4gal), globo (gal1-
4gal), isoglobo (gal1-3gal) lacto (gal1-3glcNAc1-3gal), and neolacto (gal1-
4glcNAc1-3gal). Thus, UDP-GlcCer glucosyltransferase, which generates the Cer 
monohexoside precursor of LacCer, is a major control point for the regulation of GSLs 
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biosynthesis (Lingwood, 2011; rev. in Merrill, 2011; rev. in Yu et al., 2004, rev. in Zeng 
and Yu, 2008). 
 
 
Figure 1.5. Sphingolipids metabolism. (1) De novo synthesis of SLs occurs in the 
endoplasmatic reticulum (ER). Ceramide (Cer) formed in this compartment is transported to the 
Golgi complex (GC), which is the site of synthesis of sphingomyelin (SM) and glucosylceramide 
(GlcCer), with the latter serving as the precursor for complex SLs (glicosphingolipids, GLSs). The 
transport of Cer to the GC occurs either through the action of the transfer protein CERT, which 
specifically delivers Cer for SM synthesis, or through vesicular transport, which delivers Cer for the 
synthesis of GlcCer. Delivery of SM and GSLs to the plasma membrane (PM) appears to occur by 
vesicular transport. (2) Sphingomyelinase pathway: The breakdown of sphingomyelin by aSMase 
occurs within the endo-lysosomal system, at the outer leaflet of the PM, and in association with 
lipoproteins. In endo-lysosomal system, SM and GlcCer are degraded by the actions of 
sphingomielinases (SMases) and glucosidases (GCase) to form Cer. By the action of acid or 
neutral ceramidases (aCDase, nCDase), Cer is hydrolysed to yield free sphingosine (Sph). Sph 
can be the substrate for either ceramide sintase (CerS), via the (3) ceramide salvage pathway or 
sphingosine kinases (SphK) to form cer and sphingosine-1-phosphate, respectively. CerS, 
ceramide synthase; DES, dihydroceramide desaturase; GCS, glucoceramide synthase; SL, 
sphingolipid SMS, sohingomyelin synthase; SPT, serine palmitoyltransferase. Figure taken from 
rev in. Jenkins et al., 2009.  
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I.2.2.2. Sphingomyelin cycle 
 SM hydrolysis, the second Cer-generating pathway, involves the hydrolysis of the 
phosphocholine head group from SM by a small family of SMases. Cer is then hydrolysed 
in Sph and fatty acid by the action of ceramidases.  
 SMases (EC 3.1.4.12) are distinguished by their optimal pH and/or subcellular 
location. To date several SMases have been characterized: lysosomal SMase (aSMase), 
zinc ion-dependent secretory SMase (sSMase), neutral magnesium ion-dependent SMase 
(nSMase), and alkaline SMase (bSMase) (rev. in Marchesini and Hannun, 2004). The 
breakdown of SM occurs at the outer leaflet of the PM, in association with lipoproteins, 
and within the endolysosomal system (rev. in Jenkins et al., 2009). Because PM is 
enriched in SMS2 as well as in aSMase, PM Cer levels are likely to be balanced by the 
activities of these two enzymes.  
 Regarding the ceramidases (EC 3.5.1.23), five have been cloned and are categorized 
as acid, neutral or alkaline ceramidases, depending on the optimum pH of their enzymatic 
activity being pH 4.5 for acid ceramidase (AC, ASAH1 gene), pH 7-9 for neutral 
ceramidase (ASAH2 gene) and pH 8.5-9.5 for alkaline ceramidases (encoded by 
ASAH3/ACER1, ACER2 and ACER3 genes) (rev. in Canals et al., 2011). These distinct 
ceramidases are found in diverse cellular compartments: AC in the lysosomes (Koch et 
al., 1996), neutral ceramidase at the PM, intracellular compartments and secreted in the 
intestinal lumen (El Bawab et al., 2000), and ACER family in the ER-Golgi network (Mao 
et al., 2001; Xu et al., 2006). Thus, it is thought that ceramidases should have a crucial 
role in regulating not only the hydrolysis of Cer but also in the formation of Sph and 
sphingosine-1-phosphate, thereby controlling cellular responses mediated by these 
bioactive lipids (rev. in Mao and Obeid, 2008). Cer-1-phosphate (Cer1P) is produced by 
the transfer of phosphate (from ATP) to Cer by Cer kinase, presumably located at the 
cytosolic leaflet of cellular membranes (Van Overloop et al., 2006). 
 
I.2.2.2.1. Acid sphingomyelinase 
Although primarily a lysosomal protein, aSMase can also be secreted through 
alternative trafficking of a shared protein precursor (pro-aSMase), giving rise to secretory 
aSMase (sSMase).   
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The aSMase is first synthesized as a pre-pro-enzyme (75 kDa) representing the full-
length, N-glycosylated protein. The pre-pro-aSMase is rapidly processed to pro-aSMase 
(72 kDa), and within the acidic compartment matures to a 70 kDa form, and lastly is 
processed to a 52 kDa polypeptide (Hurwitz et al., 1994b). Several evidences suggest that 
70 kDa and/or 52 kDa forms represent the lysosomal SMase (Ferlinz et al., 1994; Hurwitz 
et al., 1994a). aSMase arises from mannose-6-phosphorylation of N-glycans. The 
precursors that are not mannose-6-phosphorylated get directed to the Golgi secretory 
pathway and released extracellularly giving rise to sSMase (Schissel et al., 1996, 1998). 
However, given the lack of investigation into the Zn-requirement of these different forms of 
aSMase, the precise molecular identity of the mature, Zn-independent aSMase remains 
unclear.  
In addition to its importance in preserving lysosomal function, aSMase has also been 
reported to be regulated by various cellular stressors to promote Cer formation (rev. in 
Gulbins and Li, 2006). Consequently, the aSMase/Cer pathway has been considered a 
major component of the acute cellular stress response (rev. in Zeidan and Hannun, 2010). 
Its physiological relevance is also illustrated by the severity of the lysosomal disease 
Niemann-Pick types A (NPA) and B (NPB) which is caused by mutations in the gene 
encoding aSMase (SMPD1). NPA, characterized by neurodegeneration, is the infantile 
form of the disease and is lethal by the age of 2-3 years. NPB is the later-onset form and 
distinguished by progressive hepatosplenomegaly, pulmonary insufficiency and heart 
disease (rev. in Schuchman, 2009). Common between infants with NPA and most patients 
with NPB is interstitial lung disease caused by SM storage in pulmonary macrophages 
(rev. in Minai et al., 2000). 
 
I.2.2.3. Lysosomal catabolism  
 Cer can also be produced by the catabolism of complex SLs, as displayed in Figure 
1.6. Through a series of events referred to as SL recycling or the salvage pathway, SM 
and GSLs are degraded within acidic cellular compartments (LE and lysosomes) by 
resident enzymes. The catabolism of SLs is ensured by the sequential action of a series 
of lysosomal hydrolases. The first stage is the step-wise removal of monosaccharides by 
exoglycosidases from the non-reducing ends of the glycan moieties. Subsequently, the 
GSLs degradation pathways converge on the next three molecules, LacCer, GlcCer and 
lastly Cer, which is degraded to Sph (rev. in Winchester, 2005). Unlike Cer, Sph is able to 
cross the lysosomal membrane to be reutilized or further broken down (Chatelut et al., 
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1998; Riboni et al., 1998). The Sph can be converted to Cer by Cer synthase (salvage 
pathway) or phosphorylated by Sph kinase in Sph1P (Smith and Merrill, 1995). Because 
this is the only way for the formation of Sph1P, the cellular amount of this metabolite is 
highly dependent on Sph available in the cell. The importance of this pathway is 
represented by the severity of specific inherited defects, the sphingolipidoses, next 
described. 
 
I.3. SPHINGOLIPIDOSES 
 Sphingolipidoses are a class of lysosomal storage diseases (LSDs), characterized by 
SL deposition due to defects in genes encoding proteins involved in the lysosomal 
degradation of SLs or their proteinaceous cofactors (Figure 1.6.). Consequently, the SL 
substrate for the defective protein accumulates in affected cells (rev. in Raas-Rothschild 
et al., 2004). These diseases were grouped according to the identity of the storage 
material (rev. in Kolter and Sandhoff, 1998). Their mode of inheritance is autosomal 
recessive with the exception of Fabry disease which presents an X-linked inheritance 
pattern (rev. in Desnick et al., 2001).  
 
Figure 1.6. Sphingolipid catabolism and sphingolipidoses. Disease-caused enzyme 
deficiency and activator proteins (SAP) required for the respective degradation step in vivo are 
indicated. Figure taken from rev. in Kolter and Sandhoff, 2006. 
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 Clinical presentation (Table 1.1) varies with the specific subtype of the disease, but 
common features include neurological symptoms like dementia, major psychiatric 
illnesses, cerebral palsy, developmental delay, rarefaction of the bones, and several 
somatic symptoms, such as hepatomegaly and splenomegaly (rev. in Fletcher, 2006; 
Staretz-Chacham et al., 2009). In addition, detailed medical description can be found in 
the Online Metabolic and Molecular Bases of Inherited Disease (OMMBID) website.  
 Sphingolipidoses are rare inborn diseases but highly mortal. Overall frequencies of 
occurrence of LSDs have been reported for several countries (Meikle et al., 1999; 
Poorthuis et al., 1999; Applegarth et al., 2000; Dionisi-Vici et al., 2002; Pinto et al., 2004), 
while other reports focused on LSD groups or on particular LSDs. In certain ethnic groups, 
as in Ashkenazi Jews, specific LSDs attain a particularly high frequency (Genetics Home 
Reference). In the general population, the combined incidence of LSDs is estimated to be 
1 in 5,000-7,000 live births (Fletcher, 2006; Fuller et al., 2006), being considered the most 
common cause of pediatric neurodegenerative diseases.  Even so, it is believed that the 
value is underestimated because of the possible undiagnosed or misdiagnosed cases. 
The prevalence in Portugal is estimated in 1:4,000 live births (Pinto et al., 2004). 
 
I.3.1. Primary alterations 
 The primary causes sphingolipidoses and major organs involved are described in 
Table 1.1. The primary substrate that accumulates in the lysosome, i.e. the substrate for 
the enzyme deficiency, leads to a range of pathology that can involve the liver, spleen, 
kidney, bone and central nervous system. For all these diseases the associated gene is 
known and hundred mutations described thus far (rev. in Filocamo and Morrone, 2011; 
Staretz-Chacham et al., 2009).  
 Onset and severity of the storage disease is partly determined by the residual 
activity of the gene product in the lysosomes (rev. in Conzelmann and Sandhoff, 1983,84; 
Leinekugel et al., 1992). A complete deficiency of a lysosomal enzyme leads to an early 
onset and a severe course of the disease, whereas only a few percent of residual activity 
can be sufficient to delay the onset of the disease, cause an attenuated course, and lead 
to the often misdiagnosed adult forms of the diseases (rev. in Rapola, 1994). Although this 
is valid for most of the LSDs, patients with identical genotype and, accordingly, formal 
similar residual activity, can undergo different courses of a disease. Apparently, other 
genetic and epigenetic factors may contribute to the expression of a disease in an
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Table 1.1. Clinical, biochemical and genetic basis of sphingolipidoses.  
 
 
Legend: CNS, Central nervous system; aTypes 2 and 3; bType A; cType B. 
 
 
Major peripheral organ CNS
systems affected pathology
Globotriasylceramide 
Digalactosylceramide
 Gangliosidosis GM2
Tay-Sachs
 Gangliosidosis GM2 Spleen/liver,
Sandhoff brain
Spleen/liver,
bone marrow
 Metachromatic  Sulphatide
 leucodystrophy Lactosylsulphatide
Niemann–Pick Brainb
(type A, type B) Spleen/liver, heartc
-
Gangliosidosis GM1 611458
 Farber
Fabry -Galactosidase  Xq22; GLA 301500
 Acid ceramidase 
+GM1--galactosidase  GM1 ganglioside,  keratan sulfate 
+
+
Glucosylceramidase  Glucosylceramide 1q21; GBA +ª
24520014q31; GALC
+b
+2280008p22-p21.3; ASAH1Ceramide
 22q13; ARSA 250100 +
272800 +
606463
Brain
3p21.33; GLB1 
GM2 ganglioside 15q24,2;  HEXA 272800
Sphingomyelinase  Sphingomyelin  11p15.1-p15.4; SMPD1
Arylsulphatase A
121
152
Gaucher
 Galactosylceramide -GalactosylceramidaseKrabbe 
126
41
334
78
-Hexosaminidase A + B GM2 ganglioside 5p13;  HEXB 
-Hexosaminidase A 
# mutation
Kidney, heart
Skeleton, heart
Heart
Skeleton, laryngeal
Liver, eyes and brain
Disease OMIM No.Inheritance and Gene Main storage materials Defective protein
607608
517
23
125
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individual patient (rev. in Kolter and Sandhoff, 2006). Such diverse and extensive array of 
clinical manifestations suggests that many secondary biochemical pathways involving, but 
not limited to, SLs must also be affected. 
 
I.3.2. Secondary alterations 
 Although primary enzymatic defects and the resulting clinical phenotype have been 
well characterized for LSDs, little is known about the sequence of biochemical and cellular 
events that lead to the pathology.  
 A characteristic feature of sphingolipidoses is the accumulation of other lipids as 
secondary storage products (rev. in Walkley and Vanier, 2009). These arise from the lipid 
nature of the primary storage compounds that co-precipitate other hydrophobic material 
and produce a kind of traffic jam (rev. in Aridor and Hannan, 2000, 2002). For example, 
the pathological accumulation of the SL that are not degraded due to mutant enzymes 
perturbs the cholesterol homeostasis and consequently, changes the composition of the 
membrane leading to problematic sphingolipid transport (rev. in Pagano, 2003; rev. in 
Pagano et al., 2000). Thus, several factors, not mutually exclusive, have been implicated 
in LSDs: lipid trafficking abnormalities, mitochondria dysfunction, autophagy, apoptosis, 
calcium homeostasis disruption, cellular metabolic stress and inflammation. In the case of 
sphingolipidoses, cells deficient in lysosomal enzymes or soluble non-enzymatic proteins 
(e.g. SAP) accumulate excessive levels of undegraded molecules (enzyme deficiency) or 
catabolic product (efflux permease deficiency) in endo/autolysosomes.  The excessive 
level of these molecules inhibits catabolic enzymes and permeases that are not 
genetically deficient, resulting in secondary substrate storage (rev. in Walkley and Vanier, 
2009; rev. in Platt et al., 2012; rev. in Prinetti et al., 2011). The accumulation of primary 
and secondary substrates triggers a cascade of events that may impact not only the 
endosomal-autophagic-lysosomal system, but also other organelles, including 
mitochondria, peroxisomes, nucleus, ER, GC and overall cell function (Figure 1.7).  
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Figure 1.7. Hypothetical cascade of pathological events in LSDs. Mutation in genes 
coding for lysosomal proteins cause the accumulation of undegraded macromolecules (enzyme 
deficiency) or monomeric catabolic products (efflux permease deficiency), increasing the number of 
endo/autolysosomes in cellular cytoplasm. This event can affect enzymes that are not genetically 
deficient resulting in secondary substrate accumulation. The accumulation of primary and 
secondary substrates may have impact not only in the endosomal-autophagic-lysosomal system, 
but also in other organelles, including mitochondria, the ER, GC, peroxisomes and in overall cell 
function. ER, endoplasmatic reticulum; GC, Golgi complex; LE, late endosomes. Figure adapted 
from rev in. Platt et al., 2012. 
 
I.3.3. Therapy 
 
 Many of the discussed disorders remain untreatable. However, over the past two 
decades there has been a considerable expansion in the number of therapeutic strategies 
for LSDs. The theoretical basis for the therapeutic approaches toward sphingolipidoses is 
the “threshold theory” (rev. in Conzelmann and Sandhoff, 1983,84). According to this 
theory, the ratio of substrate influx into the lysosomes and the degradation capacity 
determines the onset and severity of the diseases. Both parameters can be addressed by 
therapeutic approaches, and the theory predicts that already slight changes in this ratio 
can improve the condition of the patients (rev. in Kolter and Sandhoff, 2006). The 
objective of most therapies reported for sphingolipidoses is the restoration of the defective 
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degradation capacity within the lysosome. In principle, the earlier they are applied, more 
successful the therapy will be. 
 Current therapeutic strategies in use or under evaluation are enzyme replacement 
therapy, bone marrow transplantation, hematopoietic stem cell transplantation, gene 
therapy, substrate reduction therapy and enzyme stabilization (rev. in Boyd et al., 2013; 
Desnick and Schuchman, 2002; Gatt and Dagan, 2012; Jeyakumar et al., 2005; Platt and 
Lachmann, 2009).  
 
I.4. FARBER DISEASE 
 The deficiency in human AC activity, caused by mutations in ASAH1 gene, leads to 
Farber disease (FD, Farber Lipogranulomatosis), a rare LSD with an autosomal recessive 
mode of inheritance. Less than 100 cases have been reported thus far. This disease is 
characterized by the accumulation of Cer in several cell types (rev. in Levade et al., 2009). 
 
I.4.1. The ASAH1 gene  
 The human ASAH1 gene (OMIM 613468) spans about 30kb on chromosome 8p21.3-
p22 and comprises 14 exon and 13 introns. The full-length cDNA contains an open 
reading frame of 1185 bp, an 1110-bp 3´untranslated sequence, and an 18-bp poly(A) tail 
which translation gives rises to a 395 amino acid polypeptide with a calculated molecular 
mass of this polypeptide being ~44kDa, (Koch et al., 1996; Li et al., 1999). The cDNA 
encoding murine AC has also been cloned and it was found to have ~80% identity and 
~90% homology with human AC (Li et al., 1999). Multiple transcript variants encoding 
several distinct isoforms have been identified for this gene (Ensembl genome database: 
ENSG00000104763). 
 AC expression, assessed to date in only a small number of tissues, was found to be 
highest in heart and kidney, with moderate expression in placenta, lung and skeletal 
muscle (rev. in Zeidan et al., 2008). 
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I.4.2. Biosynthesis and maturation of AC 
 The maturation of the precursor polypeptide from the ER through the Golgi involves 
acquisition and processing of 5-6 predicted N-linked glycosylations sites, resulting in the 
increase of the molecular mass of the polypeptide from the expected 44kDa to 53-55kDa 
(Ferlinz et al., 2001). The precursor is autoproteolytically processed at the α subunit 
(13kDa) and β subunit (40kDa), linked by a disulfide bridge at Cys 143, in LE or lysosome 
(Bernardo et al., 1995; Ferlinz et al., 2001; Shtraizent et al., 2008). Cleavage of the 
precursor protein is most likely an autoproteolytic event with Cys143, Arg159, and Asp162 
as a functional triad. Only the precursor form and the β subunit have N-glycosylation sites 
and site-directed mutagenesis confirmed the importance of 5 putative N-linked 
glycosylation sites for proper proteolytic processing and full enzymatic activity (Ferlinz et 
al., 2001; Schulze et al., 2007). Several experimental evidences obtained by studying the 
molecular forms of AC present in secretions of cells treated with lysosomotropic agents, I-
cell fibroblasts (cells with mutated UDP-N-acetylglucosamine-1-phosphotransferase, the 
enzyme that catalyzes the formation of M6P in mannose-rich oligosaccharides) and M6P 
receptor deficient fibroblasts (Ferlinz et al., 2001) suggest that the precursor form of AC is 
transported to lysosome via M6P pathway.  
 
I.4.3. Protein function 
 In addition to the hydrolysis of Cer into Sph and free fatty acid, the AC has the ability 
to synthesize Cer from Sph and fatty acid. However, while the hydrolysis reaction occurs 
at pH 4.5, the reverse reaction in vitro occurs at an optimum pH of 6.0 (Okino et al., 2003), 
suggesting that both reactions occur in distinct cellular compartments. This possibility 
would imply a unique mode of regulation of AC enzymatic activity since in some places it 
could promote the degradation of Cer, and in others its synthesis. However, the possibility 
that both reactions occur in different extent in the same cell compartment cannot be 
presently excluded. 
 The degradation of membrane-bound Cer by AC requires the presence of SAP, such 
as SAP-D, but also SAP-C and SAP-A.  In vitro these saponins stimulate Cer hydrolysis in 
the presence of particular anionic phospholipids such as bis(monoacylglycero)phosphate 
(BMP) or phosphatidylinositol (Linke et al., 2001). The most effective stimulator, however, 
is BMP, a lipid that was localized on internal membrane structures of fibroblasts 
lysosomes (Kobayashi et al., 1998).  
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 Immunoprecipitation studies demonstrated that AC, aSMase and -galactosidase 
(Glase) activities in chinese hamster ovary media were co-precipitated using anti-AC 
antibodies, suggesting that the enzyme can be part of a multienzyme complex that 
integrates aSMase and Glase (He et al. 2003).  
 
I.4.4. Disease’s clinical presentation 
 The first case of FD was described and characterized in 1957 by Sidney Farber 
(Farber et al., 1957), but only in 1972 the inherited deficiency of AC activity was found to 
be the cause of this disorder (Sugita et al., 1972).  
 The clinical presentation of FD is characterized by the appearance of subcutaneous 
skin nodules, ordinarily near the joints, most often interphalangeal, wrist, elbow and ankle 
joints, or over points of mechanical pressure. These manifestations are very painful and 
lead to progressive joint stiffness, limitation of motion by contractures and finally to 
immobilization and deformation of joints. Also, characteristic signs of FD are the 
development of a progressive hoarseness due to laryngeal involvement and premature 
death. Hepatosplenomegaly and nervous system dysfunctions may also occur (rev. in 
Moser et al., 2001). At nervous system level, the main alteration found in the majority of 
autopsied patients was the accumulation of storage material in the neuronal cytoplasm 
(Moser et al., 1969). The lungs are involved in all severely affected patients, with the 
interalveolar septa and alveoli infiltrated by massive numbers of macrophages. 
Granulomatous nodules are also found on the parietal pleura. A few patients showed 
heart involvement with a thickening and nodule formation on the mitral and aortic valves 
and the chordae tendineae. Lesions are variably found in other sites, including the lymph 
nodes, intestine, spleen, kidney, tongue, thymus, gallbladder, epithelium, and liver (rev. in 
Levade et al., 2009).   
 Based on the clinical severity, age at onset and sites of major tissue involvement, FD 
has been classified into 7 subtypes. The underlying cause of subtypes 1–5 (classical, 
intermediate, mild, neonatal, neurologic progression) is the deficiency of AC (rev. in 
Levade et al., 2009; Park and Schuchman, 2006), while subtype 6 occurs as a result of 
coincidental combination of FD and Sandhoff disease (Fusch et al., 1989; Levade et al., 
1995a) and subtype 7 is due to sphingolipid activator prosaposin deficiency (the precursor 
protein of four SAPs, A-D), leading to lack of acid ceramidase, -Galalctocerebrosidase 
(GalCase) and GlcCase activities (Harzer et al., 1989; Schnabel et al., 1992). This data 
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demonstrated, for the first time, that AC requires an intact prosaposin gene (Kishimoto et 
al., 1992) for in vivo function.   
 Subtypes 1 to 3 are the most common forms of the disease. Subtype 1 patients 
(classical, early infantile onset variant) have a very severe phenotype and most die by 2 
years of age. A majority have neurological involvement and lung disease in addition to the 
characteristic findings mentioned above (rev. in Moser et al., 2001). So far, thirty-five 
patients presented the classic phenotype (rev. in Levade et al., 2009). Subtypes 2 
(intermediate) and 3 (mild) FD patients generally have milder signs and symptoms, living 
longer than those with subtype 1. They still have granulomatous inflammation leading to 
subcutaneous nodules, joint pain and contractures, hoarseness, growth deficit, respiratory 
involvement and intellectual disability, showing only slight or no symptoms of central 
nervous system disease (rev. in Moser et al., 2001). Twenty-five patients were assigned 
to the intermediate–mild phenotype (rev. in Levade et al., 2009). 
 Subtype 4 of FD is an extremely rare, neonatal form of the disease that presents 
severe neurologic deterioration and large hepatosplenomegaly already in the neonatal 
period. Only 8 patients with this form have been described (Antonarakis et al., 1984; 
Kattner et al., 1997; Levade et al., 1995c; Pierpont et al., 1983; Schäfer et al., 1996; Willis 
et al., 2008) and most severely involved patient presented hydrops fetalis and died on the 
third day. At this early age, these patients lack the characteristic clinical features of classic 
FD and, therefore, diagnosis depends on enzymatic and biochemical assays. 
 Subtype 5 of FD is characterized by progressive neurologic deterioration and, in 
some cases, tetraplegia, loss of speech, myoclonia, seizures and mental retardation are 
observed (Eviatar et al., 1986). The survival is up to 5 years of age.  
 Subtype 6 has been described in only one patient, a 6-month-old girl of 
consanguineous parents presented with hoarseness, stridor, scattered skin nodules, 
painful swelling of hand joints and ankles, and cherry-red macular spots. Until the age of 2 
years her motor and physical condition deteriorated distinctly, however her mental state 
remained unchanged. Fibroblasts from this patient presented accumulation of ceramide, 
profoundly decreased of AC activity as well as total -hexosaminidase (HexT) activity, 
corresponding to a biochemically established combination of Farber and Sandhoff disease 
(Fusch et al., 1989). 
 Subtype 7 has been reported in four cases, all presenting severe neonatal 
manifestations and storage of multiple lipids, including Cer (Elleder et al., 2005; Harzer et 
al., 1989; Hulková et al., 2001; Schnabel et al., 1992).  
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I.4.5. Molecular basis of the disease 
 In typical cases of FD, such as subtype 1, the observation of the clinical triad of 
subcutaneous nodules, joint and laryngeal involvement confirms the disease. The 
demonstration of typical histopathologic features on biopsy, showing granulomas with 
macrophages containing lipid cytoplasmic inclusions in subcutaneous nodules or other 
tissue; or the presence of Farber bodies (comma-shaped curvilinear tubular structures) by 
electron microscopy are also established diagnostic tests for FD (Faber, 1957; Moser et 
al., 2001; rev. in Park and Schuchman, 2006; Zarbin et al., 1985). When typical features 
are missing or laboratorial confirmation is required, diagnosis could be confirmed by the 
demonstration of reduced AC enzymatic activity and abnormally high Cer levels. 
  
I.4.5.1. Enzymatic deficiency and ceramide storage 
 The demonstration of reduced AC enzymatic activity can be obtained in cultured skin 
fibroblasts (Dulaney et al., 1976), white blood cells (Antonarakis et al., 1984), amniocytes 
(Fensom et al., 1979), plasma (Ben-Yoseph et al., 1989) and postmortem tissues (Sugita 
et al., 1972), or by loading studies with labeled precursors in cultured cells (Levade et al., 
2009).  
 In AC enzymatic assays, N-oleoyl Sph (Dulaney et al., 1976; Dulaney and Moser, 
1977; Fensom et al., 1979; Sugita et al., 1972) was the first and the most commonly used 
substrate. Then, experiments with the substrate N-lauroylsphingosine (Ben-Yoseph et al., 
1989; Momoi et al., 1982) have been performed due to its higher sensitivity and 
specificity. In 2010, Bedia and colleagues reported a new method for the determination of 
AC enzymatic activity using the fluorogenic substrate Rbm14-12. This method presents 
several advantages: the use of a non-radiolabeled and water-soluble analog of Cer as 
substrate and the stability of the substrate solution of at least 6 months. The assay does 
not require separation of the product from the substrate, is very sensitive and fast, and 
requires a few amount of cell lysates, being applicable to a wide variety of biological 
materials.  
 The loading tests consists in the addition of exogenous radiolabeled SLs like Cer 
(Chen et al., 1981; Sutrina and Chen, 1982), sulfatide (Inui et al., 1987; Kudoh and 
Wenger, 1982), or SM (Levade et al., 1995c), on cultured living cells to study their 
metabolism. These studies permit the evaluation of the turnover and subcellular 
compartmentalization of the SLs molecules. Its use in routine procedures is, however, 
Introduction 
 27
unfeasible due to its complexity, long execution time and the need of expertise for data 
interpretation and validation.  
 Another diagnostic approach is the demonstration of abnormally high Cer levels in 
cultured cells, biopsy samples or urine, by thin-layer chromatography (Moser et al., 1969; 
Ozaki et al., 1978), high-performance liquid chromatography (Iwamori et al., 1979; Sugita 
et al., 1974; Yahara et al., 1980) or gas-liquid chromatography combined with mass 
spectrometry (Samuelsson and Zetterstrom, 1971), or through the use of the 
diacylglycerol kinase assay in the presence of [32P]ATP to measure the radiolabeled 
Cer1P produced, a 10 times more sensitive technique than the high-performance liquid 
chromatography (Chatelut et al., 1996). 
 Mutation analysis should also be considered when the primary defect of the proband 
is identified and the knowledge of the mutations segregated within a family contribute for a 
better accuracy of genetic counseling and carrier identification in the families at risk for 
FD.  
 
I.4.5.2. ASAH1 gene defects 
 To date a total of 23 different mutations in the ASAH1 gene have been found in 20 FD 
patients of different geographical origins (Table 1.2), mostly missense mutations (17/23).  
 So far no direct correlation between the genotype, level of residual enzymatic activity, 
measured in vitro in detergent-based assay systems, and the phenotype of FD has been 
established. However, an inverse correlation between residual Cer turnover, measured in 
intact cultured cells, and disease severity has been observed (Levade et al., 1995b). 
Therefore, it is possible that correlation of the disease’s clinical severity with the genotype 
has not yet been properly assessed because only a very limited number of patients have 
been genotyped thus far.  
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Table 1.2. Review of the literature: genotype-phenotype correlations. 
   
Legend: del, Deletion; F, Female; M, Male; m, Months; NI, Not indicated; y,Years.  
DNA change Exon Protein change  Other allele Sex  Origin Onset Age of Death Subtype Consanguinity AC activity
c.66G>C 1 Q22H NI NI NI NI NI NI NI NI
c.67C>G 1 H23D NI NI NI NI NI NI NI NI
c.107A>G 2 Y36C Y36C M Tunisian NA 2y 1 Yes <5% 
c.286_288del 4 V96del V96del M Japonese 8m 6,3y 2 Yes 37%
c.290T>A 4 V97E G235R F Japonese 10m >10y 2//3 No 35%
c.703G>C 9  G235R V97E 2%
c.290T>G 4 V97G V97G M Saudi Arabia 3m NI 1 Yes NI
F 9m
 
c.383-457del 6 G128_K152del; D331N  F NI NI >1.5 y 3 No NI
c.412G>T
 E138X
c.991G>A 12 D331N  G128_K152del; 
 E138X
c.413A>T 6 E138V E138V F Sicilian 20m 30y 3 NI 5%
c.383-457del G128_K152del; G128_K152del; 
IVS6+4A>G NI NI NI F Indian 1y 1,3y 1//5 Yes NI
c.502G>T 7 G168W G168W M Croation 2w-4m 38,5m 1 No NI
c.544C>G 8  L182V  L182V F Indian 1m 6m 1 Yes NI
M NI 2y
c.533 T> C 8 W185R NI F  Emirati (Balochi) 8m - 2 No NI
c.1144 A> C 13 K382Q NI
c.665C>A 9 T222K T222K F Belgium NI 22m 1 Yes 5%
c.760A>G 10 R254G NI NI NI NI 3y 1 NI <10% 
c.833C>T 11 P278L P278L M NI 10m  >1.3  2/3 NI NI
c.958A>G 12 N320D N320D F Turkish 2,5y 6y 6 Yes 10%
IVS13+1G>T 13 N348_K366del NF M NI NI 3y 5 NI <15% 
c.1085C>G 13 P362R P362R NI NI NI 1,5y 1 Yes <5% 
c.1085C>G 13 P362R NI NI NI NI 8y 2/3 NI NI
c.1187insT 14 X396L NI NI NI NI NI NI NI NI
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I.4.6. Pathophysiology 
 As mentioned above, FD is a very rare autosomal recessive disorder, and less than 
100 cases have been reported since the first description in 1957. Due to the extremely 
small patient population, the natural history and underlying pathophysiology of this 
disease is poorly described. 
 The main pathologic feature of disease appears to be the accumulation of 
macrophages causing granulomatous infiltrations in the subcutaneous tissues, joints, liver, 
spleen, lymphoid tissue, thymus and lungs (Antonarakis et al., 1984).  The etiology of FD 
is the lack of acid ceramidase, and subsequently there is an increased storage of Cer in 
several organs and tissues (Moser et al., 2001). The principal symptoms of disease, 
mainly in the patients without involvement of the central nervous system, are caused by 
dysregulation of leukocyte functions (Burek et al., 2001), implicating the dysfunction of the 
immune system that results in the inflammatory component of the disorder with painful 
swelling of several joints, granuloma formation, contractures and inflammatory airway 
involvement (rev. in Ehlert et al., 2007). Of note, recently ASAH1 gene mutations have 
been described in patients with spinal muscular atrophy associated with progressive 
myoclonic epilepsy (Zhou et al., 2012). Nevertheless, the molecular mechanisms 
underlying the Cer accumulation to chronic granulomatous inflammation is not yet fully 
understood.  
 Cer has been shown to be implicated in many cellular events including response to 
stress (rev. in Andrieu-Abadie et al., 2001; rev. in Hannun and Obeid, 2002), regulation of 
cell growth and differentiation (rev. in Bieberich, 2011), cell migration and adhesion (Hla, 
2004) and cell senescence (Webb et al., 2010). Roles for Cer and its downstream 
metabolites have also been suggested in a number of pathological states including cancer 
(Ponnusamy et al., 2010; rev. in Zeidan et al., 2008), neurodegeneration (rev. in Jana et 
al., 2009), obesity, diabetes (Amati et al., 2011; rev. in Bikman and Summers, 2011), 
immune inflammatory responses (rev. in Pandey et al., 2008) and apoptosis (rev. in 
Mullen and Obeid, 2012). How these bioactive functions of Cer could be directly relevant 
to the Farber pathogenesis remains ambiguous, since these signaling pathways appear to 
involve specific non-lysosomal pools of Cer (Birbes et al., 2001; Zhang et al., 1997). As a 
matter of fact, studies performed by Tohyama and colleagues (1999), indicated that 
despite the levels of Cer in cultured skin fibroblasts of four Farber patients were 2.9 fold 
higher, these cells do not exhibit different apoptotic features comparing to control cells. In 
another study, fibroblast or lymphoid cell types of FD patients stimulated with TNF-, anti-
CD95 or CD40 antibodies, anthracycline, or ionizing radiation, as well as cell permeant 
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ceramides, underwent apoptosis just as control cells (Ségui et al., 2000). These results 
agree with the notion that FD is characterized clinically by symptoms that do not evoke 
any abnormality of apoptotic processes (Moser, 1995). Furthermore, overexpression of 
AC had no effect in cell viability or in stress-induced apoptotic response (Ségui et al., 
2000). Taken together, these findings strongly argue against endosomal/lysosomal 
ceramide playing a role in stress-induced apoptosis and further strengthen the notion that 
the Cer produced in cells stimulated by apoptotic agents does not result from an 
endosomal/lysosomal SMase activity (Bezombes et al., 2001; Ségui et al., 2000). Indeed, 
there are different intracellular pools of Cer and its production appears to be highly 
compartmentalized, namely at the cell surface, in caveolae, from which it can be delivered 
to specific sites of biomodulating action within the cell (Liu and Anderson, 1995). 
Therefore, the Cer accumulated in Farber cells might be without biomodulating effect on 
its cellular targets due to its localization in the lysosomes. If an extra-lysosomal 
accumulation of a signaling pool of Cer occurs in FD is presently unclear.  
 
I.4.7. Therapy 
 Currently, the therapeutic management of FD is mainly palliative. It has been focused 
on pain therapy, physical therapy, surgical correction of severe contractures and anti-
inflammatory medication. The affected patients usually die in the second decade of their 
lives as a consequence of granuloma formation in the respiratory tract, their immobility 
with recurrent episodes of pneumonia and resulting respiratory insufficiency (Moser et al., 
2001). However, some advances have been made, especially in the last decade. 
 The first reports on allogeneic hematopoietic stem cell transplantation in FD patients 
were published in 1989 and 2000 by Souillet and Yeager. The two patients with the 
classic FD phenotype subjected to treatment showed granulomas regression, a 
diminished joint discomfort, improved joint mobility, and hoarseness had diminished. 
However they died because of a deterioration of their neurological status, as in other 
lysosomal storage disorders with severe CNS disease. Starting in 2001, 3 children and 1 
adult with FD, presenting minimal CNS involvement, have been transplanted so far. High 
levels of donor chimerism were observed, and all 4 patients showed significant decrease 
in the number of granulomas as well as a general improvement in joint mobility with 
subsequent reduction in pain (rev. in Ehlert et al., 2007; Vormoor et al., 2004). Thus, 
hematopoietic stem cell transplantation has showed some promising results on patients 
with minimal central nervous system involvement.  
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 In 1999, the feasibility of gene therapy at the cellular level for FD, were tested. The 
authors, created a novel recombinant retrovirus for the transfer of the human AC cDNA 
and observed that the retrovirus mediated expression of AC in skin fibroblasts was 
accompanied not only by the increase in enzyme activity, as detected in vitro in 
transduced fibroblast extracts, but also by normal lysosomal turnover of Cer. This 
increased catabolism of Cer led to the complete correction of the metabolic defect as 
demonstrated by the reduction of accumulated intracellular Cer to normal levels (Medin et 
al., 1999). In more recent studies, in vitro assays with novel recombinant retrovirus and 
lentivirus led to the same successful results (Ramsubir et al., 2008). Then, murine models 
were developed to apply the viral vectors in vivo. The first model used was xenografts of 
vector-transduced human hematopoietic cells. The second model incorporated direct 
therapeutic lentivector injection into neonatal mice. In both cases, vector-transduced cells 
persisted in mice, and long-term transgene expression was evident over time (Ramsubir 
et al., 2008). The last advances in gene therapy approach, was the employing of lentivirus 
transduction and transplantation of primary hematopoietic cells in a non-human primate 
model, the rhesus macaques (Walia et al., 2011). The animals were followed for at least 1 
year post-transplantation to track the sustainability of the transgene in peripheral blood 
and bone marrow cells. Increases of AC enzymatic activity to supra-normal levels in 
peripheral blood cells, bone marrow cells, spleen, and liver were observed throughout the 
study period. Additionally, Cer levels were reduced due to increased AC activity even in 
these metabolically normal animals. These results show that transplantation of lentivirus 
transduced mobilized peripheral blood cells is safe and may be efficacious for FD and, by 
extension, other LSDs.  
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Farber disease is a clinically heterogeneous autosomal recessive disease caused by 
mutations in the ASAH1 gene. This gene codes for acid ceramidase, a lysosomal 
heterodimeric enzyme that acts in the last step of the sphingolipid degradation pathway by 
hydrolysing ceramide into sphingosine and fatty acid. 
In the last two decades, the identification and characterization of FD cell models have 
provided important insights into the molecular pathogenesis by extending the knowledge 
of the primary defects underlying the disease. Additionally, they have also been useful to 
define basic properties of acid ceramidase through the study of its biosynthesis, 
processing and maturation in the route to lysosomes, and also the bioactivity of lysosomal 
ceramide storage. Nonetheless, little is known about secondary or tertiary alterations 
responsible for disease’s signs or symptoms and, ultimately, associated with the disease 
onset and progression. Indeed, the correlation between the clinical phenotype and either 
the residual acid ceramidase enzymatic activity or the level of ceramide storage is still a 
controversial issue. Furthermore, very few causative mutations have been reported in the 
ASAH1 gene and for most of them the molecular mechanism is unclear, hampering the 
establishment of genotype-phenotype correlations. In addition, the disruption of ASAH1 
gene in mice was found to cause an early embryonic lethal phenotype, underscoring the 
importance of acid ceramidase in vivo for proper cell and organismal function but 
precluding its use in the study of the disease's pathobiology. Therefore, the aim of this 
study was to characterize a unique cellular model underlying the most severe form of FD 
identified to date by using genetic, molecular and biochemical approaches.  
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 This chapter describes the materials and methods used in the studies presented in 
this thesis. 
 
III.1. PATIENTS  
  The clinical phenotype and genetic alterations reported for the patients included in the 
present study are described in Table 3.1. 
 
Table 3.1. Clinical, pathological and mutational spectrum of patients.   
 
Legend:  FD, Farber disease; d, days; NPB, Niemann-Pick disease type B; NPC, Niemann-Pick disease type 
C NI, Not Indicated; MLII, Mucolipidosis type II; y, years. 
 
 
FD1 patient is the first, and to our knowledge the only, reported FD case with non-
immune hydrops fetalis (Kattner et al., 1997; Schäfer et al., 1996).  The female patient 
presented a severe, generalized edema and extreme enlargement of her liver and spleen. 
Massive histiocytic infiltration was observed in liver, spleen, bone marrow, lymph nodes, 
thymus, parotid gland and adrenal medulla. The child died 3 days after birth from 
disseminated intravascular coagulation. The diagnosis of FD, subtype 4, was based on 
FD1 German Female present s tudy present study Subtype 4 (neonatal) 0,5y 3d
FD2  
(GM20015) Tunisian Male [c.107A>G] [p.Y36C]
Subtype 1 
(classic) 0,5y 2y
FD3 
(GM20018) Belgium Female [c.665C>A] [p.T222K] 
Subtype 1 
(classic) 1y 2y
FD4 
(GM02315) Italian Female [c.413A>T]+[c.383_457del] [p.E138V]+[p.G128_K152del]
Subtype 3       
(mild) 2y 30y
NPB1 Portuguese NI [c.1426C>T]+[c.2257T>C] [p.R476W]+[p.C227R] Type B NI NI
NPB2 Portuguese NI [c.1426C>T] [p.R476W] Type B NI NI
NPB3 Portuguese NI [c.1829_31delGCC] [p.R610del] Type B NI NI
NPB4 Portuguese NI NI NI Type B NI NI
NPC Portuguese NI [c.530G>A]+[c.3591+1G>A] [p.C177Y] Type C1 NI NI
MLII Portuguese NI [c.3503_4delTC] [p.L1168fsX1172] Type II NI NI
Patient Age of death Onset FenotypeMutated proteinGenotypeSexOrigin
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the deficient enzymatic activity of AC (Kattner et al., 1997) and accumulation of Cer in 
cultured fibroblasts (Chatelut et al., 1996) and visceral organs (Schäfer et al., 1996).   
 
III.2. BIOLOGICAL SAMPLES AND CELL CULTURE  
 In this work, cultured skin fibroblasts from patients with FD, Niemann-Pick disease 
type B (NPB), Niemann-Pick disease type C (NPC), Mucolipidosises type II (MLII) and 
controls, were used.   
 Cell line FD1, corresponding to transformed fibroblasts by the human simian virus 40 
(SV40) large T antigen, and FD1-AC cells, resulting from FD1 cells transfected with a 
recombinant retroviral vector cloned with human ASAH1/cDNA (AC-transduced cells), 
were previously described (Chatelut et al., 1996; Medin et al., 1999) and kindly provided 
by Prof. Thierry Levade (Laboratoire de Biochimie Métabolique, Institut Fédératif de 
Biologie, CHU Purpan, Toulouse, France). Cell lines FD2, FD3 and FD4, were obtained 
from Coriell Institute for Medical Research Cell Line Repository (New Jersey, USA).  
 NPB, NPC, MLII, and control fibroblasts were kindly provided by Dr. Lúcia Lacerda 
(Biochemical Genetic Unit, Centre Medical Genetics, INSARJ, Porto, Portugal). Skin 
fibroblasts from control individuals were maintained anonymous throughout the study.  
 All cell lines were grown to confluency in Dulbecco's Modified Eagle Medium 
(DMEM), supplemented with 10% of fetal calf serum and 10% of Penicillin/Streptomycin 
solution, at 37ºC in an atmosphere containing 5% CO2. After trypsinization the cells were 
washed with cold phosphate buffered saline (PBS) and the pellets were frozen at -20ºC or 
immediately processed. All the cell culture reagents were purchase from Gibco®.  
 
III.3. MUTATIONAL SCREENING IN GENOMIC DNA  
 
III.3.1. ASAH1 gene 
 Genomic DNA was extracted from skin fibroblasts with ‘‘EZ1 DNA Tissue kit’’ on 
BioRobot EZ1 (Qiagen), according to manufacturer´s instructions. Genomic fragments 
(between 223 and 613 bp), mostly encompassing each exon and the corresponding 
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flanking sequence, were amplified using the forward and reverse primers listed in Table 
3.2. Polymerase chain reaction (PCR) amplifications were performed in a total reaction 
volume of 25μl using about 100ng of genomic DNA, 1x PCR ImmoMixTM Red (Bioline) 
and 0.25µM of each primer, for 35 cycles at specific annealing temperatures. After 
agarose gel electrophoresis, PCR products were purified with ExoSap-IT (Exonuclease I, 
shrimp alkaline phosphatase; GE Healthcare) according to the manufacturer’s instructions 
and sequenced in forward and reverse directions with BigDye Direct Cycle Sequencing Kit 
(Applied Biosystems) on an ABI Prism 310 automatic sequencer (Applied Biosystems). 
Raw data was analyzed with the sequence analysis software FINCH TV (Geopiza) version 
1.4.0. Comparative sequence analysis was performed using the Ensembl genome server. 
Each candidate mutation was confirmed in two independent PCR and sequencing 
reactions.  
 
III.3.2. SMPD1 gene 
 The mutational screening in the SMPD1 gene was performed similarly as described 
for ASAH1 gene. Genomic fragments (between 227 and 879 bp), mostly encompassing 
each exon and the corresponding flanking sequence were amplified using the forward and 
reverse primers listed in Table 3.3. 
 
III.4. LONG-RANGE PCR AND SEQUENCING 
 Long-range PCR was performed using the Expand Long Template PCR System 
(Roche, Applied Science) according to manufacturer’s instructions. The specific set of 
primers used to amplify the target genomic region of the ASAH1 gene was 5’ 
CAGACTTGATGTTGTCTTCACA-3’ (intron 2) and 5’-CTGAAATTTGGGCTTGCTATG-3’ 
(intron 6). The amplified fragment of 11329 bp corresponds to the nucleotides 8371-19699 
of the ASAH1 transcript sequence ENST00000262097. After preheating of 94°C for 2 min, 
samples were subjected to 30 cycles of denaturation at 94°C for 10 s, annealing at 54°C 
for 30s, and primer extension at 68°C for 8 min. In the last 20 cycles, successive 
increments of 20s were applied to the extension time. The final extension was completed 
by 8 min at 68ºC. After electrophoresis on a 2% agarose gel, the long-range PCR 
fragment was purified with ExoSap-IT and sequenced on an ABI Prism 310 automatic 
sequencer (Applied Biosystems). The mutation was confirmed by repeat PCR and 
sequencing. 
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III.5. cDNA MUTATION ANALYSIS 
 
III.5.1. ASAH1 gene 
 Total RNA was isolated from skin fibroblasts using the High Pure RNA Isolation Kit 
(Roche Applied Science). First-strand cDNA was synthesized using the Ready-To-Go™ 
You-Prime First-Strand Beads (GE Healthcare), according to the manufacturer’s 
instructions and PCR amplified in three overlapping fragments, using three sets of specific 
forward and reverse primers listed in Table 3.2, at specific annealing temperatures. PCR 
fragments were subjected to sequence analysis using the reference sequence from the 
Ensembl genome database.  
 
III.5.2. SMPD1 gene 
 cDNA mutation analysis of SMPD1 gene was performed similarly as described for 
ASAH1 gene. First-strand cDNA was PCR amplified in five overlapping fragments, using 
five sets of specific forward and reverse primers listed in Table 3.3.  
 
III.6. SEMI-QUANTITATIVE STUDIES 
 ASAH1/cDNA fragments were amplified in 25-cycles PCR reaction using specific 
primers corresponding to the amplification of the fragment 3 (Table 3.2) and analyzed by 
agarose gel electrophoresis using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
as endogenous reference gene (F5’-346GCCAAAAGGGTCATCATCTC365-3’ and R5’-
504TGGTATCGTGGAAGGACTCA523-3’ set of primers). Comparative analysis was 
performed using ImajeJ software (version 1.6.0).  
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Table 3.2. ASAH1 gene: forward and reverse primers. 
ASAH1_gDNA  Primer Foward and Reverse (5´- >3´) bp A.T (ºC) 
Exon 1 
 (-74)TTCTTTGCCTCTGCTGGAGTCCGGGGAGT(-46) 244 62 
151GTGCTGGGCAGCTTCTTTAC170 
Exon 2 
8345CAGACTTGATGTTGTCTTCACA8366 359 58 
8684TCCGATTCAAATGCCCGTCG8703 
Exon 3 
12521TGGGTAACCAAATTCTACACTGC12543 481 58 
12738GCTATGATGCTTAAATCTTTTATTTCT12764 
Exon 4 
13986GATGGTGCTACTGCACTCCA14005 281 64 
14318GCAACCTCTTCGCAGGGACT14337 
Exon 5 
16625GTCCAAGAACTAGATTTCAAAGCA16648 613 62 
17014AGCCCAGCACTCCACGATGC17033 
Exon 6 
19392GGCCAAAGCACACACTCACAC19412 282 55 
19653CTGAAATTTGGGCTTGCTATG19673 
Exon 7 
20741GTCCAGCTTTGATTTAGAATC20761 242 58 
20963TGGTGAAACCCCGTCTCTAC20982 
Exon 8 
21495TTGATCGTGGTGACTCGGTAA21515 321 58 
21795TGTCCTGTTACCGTTATGTAA21815 
Exon 9-10 
22240TTACATAACGGTAACAGGAC22259 515 58 
22735CCAGCTTAATCCTTTGAGGA22754 
Exon 11-12 
24226CAGCACATGTGTCCCAGAAC24245 542 58 
24748GTTCTGGCATTTTTCTTTGG24767 
Exon 13 
25029TGGAGGGGAGGTTGATTAAA25048 223 58 
25232AGGGAAAGAATTTGGCCCTA25251 
Exon 14 
26170ACAGTGATCCTGTT26183 408 58 
26557ACCGAACACTGCAGCTGTCT26575 
ASAH1_cDNA  Primer Foward and Reverse (5´- >3´) bp A.T (ºC) 
Fragment 1 
(-13)GGCTGCTAGAGCGATGCCG6 
1204 58 1172CTTGTATAGGTTGGTGAGCA1191 
Fragment 2 
(-230)GGTAGCCTGGAAGGCTCTCT(-211) 
862 58 614CTGGCTATGTGGGCATGTTA633 
Fragment 3 
488TTGGAGTATTTCTTGGGTGG507 
822 58 1290CGGCAGGTTCTCTTTGAGTC1309 
Legend: A.T, annealing temperature; bp,Base pairs; cDNA, complementary DNA; gDNA, genomic DNA. 
Superscript numbers, position in the DNA considering the A nucleotide of the first ATG as 1. 
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Table 3.3. SMPD1 gene: forward and reverse primers. 
SMPD1_gDNA  Primer Foward and Reverse (5´- >3´) bp A.T (ºC) 
Exon 1A 
(-199)CCACCGAGAGATCAGCTGTC(-180) 595 60 
380GCTGATGCTGGTGCGCTG397 
Exon 1B 
171TCCGGCAGAGGCTCACCCTCTTTC194 227 60 
380GCTGATGCTGGTGCGCTG397 
Exon 2 
740CTCTGCTCTGCCTCTGATT758 879 55 
1565GAATGAAAGTGAAGGGAG1582 
Exon 3 
2541ACCCTCCACCCAAATGCC2558 350 55 
2870GTTTTATTTTCCTGGCATTCC2890 
Exon 4 
2870GTTTTATTTTCCTGGCATTCC2890 346 55 
3133AGTGTCTGAAGGCTGAAA3150 
Exon 5 
3243CAGATGTCTTCCTACCCC3260 255 55 
3479AGTTGGTGGGATAGGGGAA3497 
Exon 6 
3518GCAAAGCATGGGCAGGAT3534 568 60 
4067AATGCTGCTGTGGTTCAAC4085 
SMPD1_cDNA  Primer Foward and Reverse (5´- >3´) bp A.T (ºC) 
Fragment 1 
(-162)GAAGGGGCGGAGCTGCTT(-145) 
461 58 281GCAAAGGTCTATTCACCGCC300 
Fragment 2 
182CTCACCCTCTTTCTCCCC199 
587 58 751AAGTGTGACCTGCCCCTG768 
Fragment 3 
651GGGCACGGACCCTGAC666 
610 58 1243GCTGAGGATCGAGGAGAC1260 
Fragment 4 
1170GAACTTCTGGCTCTTGATCAA1190 
837 58 1988GGTGAAAGAACCAGTCCCT2006 
Fragment 5 
1654CCTACCGCCTGGCACAAC1671 
353 58 1988GGTGAAAGAACCAGTCCCT2006 
Legend: A.T,  Annealing temperature; bp,Base pairs; cDNA, Complementary DNA; gDNA, 
Genomic DNA. Superscript numbers, position in the DNA considering the A nucleotide of the 
first ATG as 1. 
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III.7. BIOINFORMATIC ANALYSIS 
 Alignments of the nucleotide sequences of the mutant and normal ASAH1 alleles 
were achieved using the Ensembl genome server. The web tool Human Splicing Finder 
(Desmet et al., 2009), version 2.4.1, was used to predict the strength of 5’ splice junctions 
in the ASAH1 gene, and potential branch points, splicing enhancers and splicing silencers 
motifs. Splice prediction by using consensus sequences was also performed with 
softwares SpliceView and MaxEnt (Yeo and Burge, 2004). The nucleotide sequences of 
the ASAH1 gene were screened for the presence of repetitive elements using the default 
settings of the RepeatMasker software, version open-4.0.1. The sequence was also 
analyzed with the non-B DNA motif search tool (nBMST), version 2.0. (Cer et al., 2013).  
 
III.8. ANTIBODIES 
 Anti-AC mouse monoclonal antibody raised against the peptide segment 88-182 of 
the human protein (MCA) was from BD Transduction Laboratories (BD Bioscience). Anti-
AC goat polyclonal antibody produced against an internal segment of the human protein 
(PCA) was from Santa Cruz Biotechnology. Rabbit polyclonal anti-AC antibody (SHA) was 
kindly provided by Prof. Konrad Sandhoff (Life and Medical Sciences Institute, University 
of Bonn, Germany). Anti-mouse and anti-rabbit secondary antibodies were from Cell 
Signalling. Anti-goat secondary antibody was from Santa Cruz Biotechnology.  
 
III.9. PROTEIN ANALYSIS BY WESTERN BLOT 
 Cell pellets from cultured fibroblasts were suspended in 1x lysis buffer (Cell 
Signalling), 1mM phenylmethanesulfonylfluoride and protein inhibitor cocktail (Roche), 
lysed by sonication on ice, followed by a 10 min centrifugation at 13,200g at 4ºC. Under 
reducing conditions, the samples were prepared with Laemmli sample buffer and 0.1M 
dithiothreitol. After heat denaturation, approximately 50 μg of protein was electrophoresed 
on 10% acrylamide gel and transferred to nitrocellulose membrane (Amersham 
Biosciences). The membrane was incubated in blocking buffer (1 x Tris-buffered saline, 
0.1% Tween-20 and 5% dried non-fat milk) for 2h, and incubated overnight at 4°C with 
primary antibody (diluted in blocking buffer). Immunoreactivity was visualized with 
horseradish-peroxidase-conjugated secondary antibody followed by chemiluminescence 
detection (Luminata Western HRP Substrates, Millipore).  
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III.10. IN VITRO ENZYMATIC ACTIVITIES 
 The AC activity was determined against the artificial fluorogenic substrate, Rbm14-12, 
kindly provided by Prof. Thierry Levade (Laboratoire de Biochimie Métabolique, Institut 
Fédératif de Biologie, CHU Purpan, Toulouse, France), as previously reported (Bedia et 
al., 2010). The aSMase activity was determined against the artificial fluorogenic substrate, 
the 6-hexadecanoylamino-4-methylumbelliferylphosphorylcholine (HMU-PC; Moscerdam, 
Netherlands), as previously described (van Diggelen et al., 2005), or against the natural 
radioactive substrate, choline-methyl-14C sphingomyelin (specific activity 54 mCi/mmol; 
PerkinElmer, California, USA) as reported (Graber et al., 1994; Jaffrézou et al., 1996; 
Wiegmann et al., 1994). The activity of -galactocerebrosidase (GalCase), -
glucocerebrosidase (GlcCase), total -hexosaminidase (HexT), and -galactosidase 
(Glase) was assayed with fluorogenic substrates labeled with 4-methylumbelliferyl: 6-
hexadecanoylamino-4-methylumbelliferyl--galactoside (Moscerdam), 4-
methylumbelliferyl--D-glucopyranoside (Glycosynth); 4-methylumbelliferyl-2-acetamido-
2-deoxy--D-glucopyranoside (Sigma) and 4-methylumbelliferyl--D-galactopyranoside 
(Sigma), respectively, as previously described (Ho and O´Brien, 1971; Ribeiro et al., 1991; 
Wiederschain et al., 1992; Sá Miranda et al., 1990). 
 
III.11. SPHINGOLIPID QUANTITATION ASSAYS 
 For Cer quantification, lipids were extracted and Cer mass measured as previously 
reported using Escherichia coli membranes as a source of diacylglycerol kinase (Preiss et 
al., 1987; Van Veldhoven et al., 1992). Radioactive ceramide-1-phosphate was isolated by 
thin layer chromatography (TLC) (Whatman LK6D plates) using 
chloroform/acetone/methanol/acetic acid/water (50:20:15:10:5, v/v/v/v/v). TLC plates were 
exposed to X-ray films. Then, lipid spots were scraped, and phosphorylated Cer and 
diacylglycerol were counted by liquid scintillation. SM was quantified by analysis of lipid 
phosphorus after alkaline methanolysis as previously described (Ames, 1966). 
 
III.12. STATISTICAL ANALYSIS 
 Data are expressed as mean values ± SD of at least three independent experiments. 
Values were compared by Student’s t-test. The 0.05 probability level was chosen as the 
point of statistical significance. 
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The intent of this chapter of the thesis is to provide an overall and integrated 
perspective of the achieved results obtained in the course of the PhD project. 
 
IV.1. ELUCIDATION OF THE GENOTYPE OF THE NEONATAL FORM OF 
FARBER DISEASE 
A German patient, representing the first, and to our knowledge the only, reported FD 
case with non-immune hydrops fetalis (Kattner et al., 1997; Schäfer et al., 1996) was 
investigated for elucidation of the mutations underlying this extremely severe and rare 
Farber’s phenotype. The diagnosis of FD, subtype 4, has been previously achieved based 
on the deficient enzymatic activity of AC (Kattner et al., 1997), and accumulation of Cer in 
cultured fibroblasts (Chatelut et al., 1996) and visceral organs (Schäfer et al., 1996).   
 
IV.1.1. Mutational analysis in gDNA and cDNA of ASAH1 gene 
 
IV.1.1.1. Identification of the novel mutation g.24491A>G in intron 11   
The genomic DNA from FD1 patient´s fibroblasts was screened for mutations by 
direct sequencing of PCR products corresponding to each of the 14 exons of the ASAH1 
gene and the corresponding intronic flanking sequences. The transition g.24491A>G 
(c.917+4A>G) in intron 11 was found in heterozygosity (Figure 4.1.A). This novel mutation 
was not detected in 100 normal control chromosomes (data not shown), discarding the 
possibility of representing a common panethnically polymorphism. No other predicted 
deleterious alteration was found in exons and flanking intron sequences of the patient’s 
sample. In accordance with patient’s genotype, the mother was heterozygous for the 
same gene defect (Figure 4.1.B), and the father’s sequence normal in this region (Figure 
4.1.C). 
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Figure 4.1. Identification of the mutation g.24491A>G. Cycle sequencing of the PCR 
products obtained from genomic DNA of FD1 patient (A) and parents (B and C) cells was 
performed as described in the Materials and Methods. The region of the electropherogram 
encompassing the exon 11/intron 11 junction is indicated by an arrow. FD1, Farber disease patient 
1; WT, Normal wild-type sequence. 
 
Since the study of genomic DNA allowed the identification of only one mutant allele, 
cDNA / ASAH1 sequencing studies were then carried out.  
 
IV.1.1.2. ASAH1 / cDNA sequencing revealed the skipping of exons 3 to 5 
The cDNA obtained from total RNA isolated from FD patient’s fibroblasts was 
amplified in 3 overlapping fragments and analyzed by agarose gel electrophoresis (Figure 
4.2). For the PCR product corresponding to the full length cDNA fragment, a faster 
migrating band than the wild-type fragment was observed after agarose gel 
electrophoresis (Figure 4.2.B, fragment 1). Similar finding was obtained for the PCR 
fragment encompassing exons 1-8 (Figure 4.2.B, fragment 2). For the cDNA-PCR 
fragment comprising exons 8 to 14 (Figure 4.2.B, fragment 3) the electrophoretic 
migration pattern found in the patient was comparable to the control. For the most 
prominent cDNA-PCR bands, DNA was purified and subjected to sequence analysis. 
 
….ATGAGTAAGT…..
….ATGAGTA(A/G)GT…...
exon11 intron11
WT
FD1
FD1 FD1_FatherFD1_Mother
A.
B. C.
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Figure 4.2. RT-PCR products generated from mRNA/ASAH1. Total RNA was isolated 
from control and FD1 patient fibroblasts and reversed transcribed into cDNA as described in the 
Materials and Methods. A. Schematic representation of the amplification strategy of cDNA/ASAH1 
in three overlapping fragments. B. Electrophoretic pattern of migration of PCR products. bp, base 
pairs; C, control; FD1, Farber disease patient 1. 
 
 
Sequencing data showed that faster migrating bands resulted from the skipping of the 
full sequence of exons 3 to 5 (c.126_382del) (Figure 4.3.A).This alteration was not 
detected in 100 normal control chromosomes (data not shown). In addition, several other 
faster migrating bands were observed (Figure 4.3.B) and sequence analysis revealed that, 
besides exons 3 to 5, other exonic fragments were also missing, most probably due to 
alternative splicing that is often over represented when mutations interfere with the cell 
splicing machinery (Morikawa et al., 2010).  In accordance with patient’s genotype, the 
father was heterozygous for the exon-skipping defect and the mother’s sequence was 
normal in this region (data not shown).  
  
15’ 3’2 3 4 5 6 10 11 12 13 14
Fragment 1
Fragment 2
Fragment 3
7 8 9
bp C FD1 bp C FD1 bp C FD1
750
1000
1000
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1000
1500
Fragment 1 
(1204 bp)
Fragment 2 
(862 bp)
Fragment 3 
(822 bp)
A.
B.
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Figure 4.3. Study of cDNA/ASAH1 PCR products: excision of exons 3 to 5. Total RNA 
was isolated from control and patient fibroblasts and reversed transcribed into cDNA as described 
in the Materials and Methods. A. Electropherogram obtained after sequencing of PCR products 
illustrating the deletion of exons 3 to 5 observed in the FD1 patient. B. Evidence of alternative 
splicing in FD patient. Electrophoretic pattern of migration of PCR products generated after the 
amplification of the full length cDNA/ASAH1 (fragment 1) is shown. For the most prominent cDNA-
PCR bands, DNA was purified and subjected to sequence analysis. Depleted exons are indicated 
in the left side of the gel. The length of mutant cDNA PCR products observed after agarose gel 
electrophoresis matched the theoretical prediction. bp, base pairs; C, control;  E, Exon; F1, 
Fragment 1;  FD1, Farber disease patient 1; M, DNA molecular weight marker.  
 
IV.1.1.3. Identification of a large ASAH1 gene deletion 
As the patient was heteroallelic for the g.24491A>G mutation and cDNA analysis 
revealed a fragment lacking the full-sequences of exons 3 to 5, the existence of a large 
deletion in the ASAH1 gene was then postulated. To investigate this hypothesis, a long-
range PCR was designed to amplify ASAH1 genomic DNA encompassing exons 2 to 6. 
After agarose gel electrophoresis, two fragments were observed in patient’s sample: the 
normal amplicon and a shorter fragment that was over-represented probably due to the 
more efficient amplification of shorter fragments often observed in long PCR analysis 
(Figure 4.4). Direct sequencing revealed a deletion of 9470 bp (g.8728_18197del), from 
3941 nucleotides before the first nucleotide of exon 3 to 1358 nucleotides after the last 
nucleotide of exon 5 (c.126-3941_382+1358del).  
 
E3-E5
E3-E6; E11; E12
E3-E5; E7- E12 500 bp
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Figure 4.4. Characterization of exons 3 to 5 deletion in ASAH1 gene. Cycle sequencing 
of the PCR products obtained from genomic DNA of patient’s cells was performed as described in 
the Materials and Methods. A.  Genomic region encompassing exons 3 to 5 (represented as 
boxes) of ASAH1 gene. The length of each intron and exon is indicated in base pairs. Long-range 
PCR was performed using a forward primer in the beginning of intron 2 and a reverse primer in 
intron 6 (represented by arrows). B. The amplification products were visualized in agarose gel 
showing a ~11 kb fragment in control and patient samples and a much more intense PCR product 
of about 1.8 kb in the patient. C. Sequencing analysis encompassing the deletion junction c.126-
3941_382+1358del. bp, base pairs; C, control; FD1, Farber disease patient 1; M, DNA molecular 
weight marker.  
 
The exact breakpoint could not be unambiguously ascertained because of the 
presence of an identical nucleotide at both ends. The most 3’ position (in the sense 
strand) was used to describe the position of the breakpoint. The deletion event generated 
a cleaned junction with no missing or inserted nucleotides. Large deletions frequently 
originate from recombination events promoted by repetitive elements present in the 
human genome (Callinan and Batzer, 2006), and breakpoints may also occur at predicted 
non-B DNA structures (rev. in Bacolla and Wells, 2009) Therefore, the DNA sequence 
flanking the 5’ and 3’ deletion breakpoints was screened for the presence of such 
elements or structures. Analysis with Repeatmasker software revealed no sequence 
homology for interspersed repeat elements across or near the deletion breakpoints. 
However, these elements are over-represented in introns 2 to 5 of the gene when 
compared with the entire gene sequence. Sequence analysis with nBMST program 
identified an inverted repeat across the 3’ deletion breakpoint and a stretch of 14 
dinucleotide repeats (AC)n located 23 nucleotides upstream of the 3’ breakpoint. 
Nevertheless, no significant homology was noticed for the intronic sequences in the 
regions flanking the deletion. 
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IV.1.1.4. Polymorphic genetic variants  
The information on gene polymorphisms may be important in future studies aiming to 
explore the importance of the backgrounds in which mutations occur. In this regard, two 
documented single nucleotide polymorphisms were found in FD1 sample: c.457+45A>G 
in intron 6 (SNP: rs2073574) and c.737T>C in exon 10 (SNP: rs10103355) (Figure 4.5).  
 
 
 
 
 
 
 
 
Figure 4.5. Single nucleotide polymorphisms in ASAH1 gene. The DNA was isolated 
from patients and parents fibroblasts and analyzed by direct cycle sequencing of PCR products as 
described in the Material and Methods. Primers are described in Table 3.2. The corresponding 
positions of SNPs in the electropherograms are indicated by arrows. A. Intron 6, c.457+45 A>G 
(SNP:rs2073574); B. Exon 10, c.737 T>C (SNP: rs10103355). FD1, Farber disease patient 1. 
 
In addition, a duplicational insertion of 29-bp in intron 5 was found in homozygosity, 
c.382+118_382+119dup29 (or c.382+118insGCTGTATGTCTTA GATATACAGCACAG 
GT) (Figure 4.6.). Several polymorphisms are documented in the region c.382+83-118 
(SNP: rs144918941; rs115973081; rs61430183; rs138234399; rs117637498; 
rs146761887; rs144722013; rs117355478; rs34633536). This observation highlights the 
highly variable nature of the sequence nearby the mutation. Indeed, the detection of the 
genetic alteration in 78 of the 100 control chromosomes (data not shown) reinforces the 
assumption of a polymorphic variant. As the insertion point is flanked by direct repeats, 
the DNA slippage model might explain the duplication observed (Figure 4.6). This model 
FD1
FD1_FatherFD1_Mother
FD1
FD1_FatherFD1_Mother
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assumes that, during the process of DNA replication, the primer strand transiently 
dissociates from the template strand, the newly synthesized second repeat slips backward 
to mispair at the first repeat and the progression of the DNA synthesis results in sequence 
duplication (rev. in Cooper and Krawczak, 1991; Oron-Karni et al., 1997).  
 
 
 
 
Figure 4.6. Characterization of the duplicational insertion in intron 5 of ASAH1 
gene. A. PCR and cycle sequencing procedure were performed as described in the Material and 
Methods. The DNA sequence at the mutation breakpoint is underlined and the corresponding 
position in the electropherogram indicated by an arrow. B. Slipped strand mispairing mechanism 
for the polymorphic duplicational insertion observed in intron 5 of the ASAH1 gene of FD1 patient. 
FD1, Farber disease patient 1; WT, Normal wild-type sequence. 
 
 
The patient’s genotype was confirmed by studying parent’s samples. The two single 
nucleotide polymorphisms c.457+45A>G in intron 6, and c.737T>C (p.Val246Ala) in exon 
1, were observed in homozygosity in the DNA samples of both parents (Figure 4.5). The 
insertion of 29-bp in intron 5, observed in a hotspot region of the gene, was transmitted by 
the mother (data not shown).  
 
 
……………ACCTTTAGGTAAAGT…….. 
exon5 intron5
+118bp
WT ACAGCACAGGTGCTGTATGTCTTAGATATACAGCACAGGT ------------------------------------------------------------GCACAGGT
ACAGCACAGGTGCTGTATGTCTTAGATATACAGCACAGGT GCTGTATGTCTTAGATATACAGCACAGGTGCACAGGT……………ACCTTTAGGTAAAGT……..
exon5 intron5
FD1
+118bp
5´
5´
3´
3´
ACAGCACAGGTGCTGTATGTCTTAGATATACAGCACAGGT GCACAGGT5´ 3´
GCTGTATGTCTTAGATATACAGCACAGGT
ACAGCACAGGTGCTGTATGTCTTAGATATACAGCACAGGT GCTGTATGTCTTAGATATACAGCACAGGTGCACAGGT5´ 3´
Backward slippage
Second replication
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IV.2. CHARACTERIZATION OF THE MUTATIONAL MOLECULAR 
MECHANISMS  
To study the biological impact of the mutations identified in FD1 patient, in silico 
prediction studies and analysis at the level of mRNA and protein was then performed.  
 
IV.2.1. Predictions from in silico analysis 
Since g.24491A>G is a novel mutation, functional studies would be needed to 
ascertain its pathogenicity. Thus, in silico analysis of this mutation was performed. In exon 
11/intron 11 splice junction two possible donor splice sites crossing the mutation were 
recognized by the web tools SpliceView, Human Splicing Finder and MaxEnt model. The 
higher the score, the higher is the probability that the sequence is a true splice site. 
Considering that the highest scored sequence, TGAgtaagt, is the true splice site, then the 
mutation g.24491A>G occurs 4 nucleotides downstream of the first position of intron 11. 
Ideal MaxEnt splice site score for 5’ss is 11.81. For the mutation g.24491A>G, MaxEnt 
model estimated the reduction of the 5´ss strength from 8.82 to 3.27 (average score for 
the donor splice site in the ASAH1 gene: 8.83). Furthermore, in addition to the splice site, 
intronic and exonic cis-elements play also an important role in splicing. For the mutation 
g.24491A>G in intron 11, Human Splicing Finder software predicts the disruption of one 
exonic splicing enhancer motif for the protein SRp55, and the creation of one exonic 
splicing enhancer motif for the protein SRp40. Moreover, the creation of one potential 
splicing silencer motif ([T/G]G[T/A]GGGG) in two positions of the splicing junction 
sequence, and the creation of three potential exonic splicing silencers-hexamers 
upstream of the transition were also noticed. These findings further support the disruption 
of the normal splicing process by the mutation g.24491A>G. 
 
IV.2.2. Impact of mutations on the mRNA and protein levels 
 
IV.2.2.1. Semi-quantitative analysis of the ASAH1 transcript 
Analysis of cDNA-PCR products, using GAPDH as endogenous gene for expression 
normalization, showed a level reduced to about 50% in FD cells when compared with the 
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control sample (Figure 4.7).  This observation suggests that g.24491A>G is likely to have 
a negligible impact on the level of the total transcript. This notion is also supported by the 
absence of a detectable band corresponding to the full length cDNA/ASAH1 in FD sample 
(Figure 4.2.A, fragment 1). The major abnormal transcript observed in patient’s cells is 
predicted to code for a shortened polypeptide resulting from the deletion of amino acids 
coded by exons 3 to 5 and the introduction of a premature stop codon due to a frameshift 
abnormality, p.Tyr42_Leu127delinsArgfs*10. 
 
 
 
Figure 4.7. Semi-quantitative analysis of cDNA/ASAH1. Total RNA was reversed 
transcribed and used for the amplification of cDNA/ASAH1 (fragment 3). For expression 
normalization, GAPDH was used as endogenous gene and the RT-PCR exponential phase was 
considered at 25 cycles for both genes. The expression level referred to as the ratio of 
ASAH1/GAPDH is shown below each lane. ASAH1, Acid ceramidase gene; bp, base pairs; C, 
control;  FD1, Farber disease patient 1;  GAPDH, Glyceraldehyde 3-phosphate dehydrogenase 
gene; M, DNA molecular weight marker. 
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IV.2.2.2. Protein analysis by Western Blot  
The molecular forms of AC present in total cell lysates from FD1, FD1-AC and control 
fibroblasts were studied by Western blot using distinct antibodies (Figure 4.8). After SDS-
PAGE (under reducing conditions, RC) and blotting, a band of about 14 kDa, 
corresponding to the -subunit, was detected with MCA and SHA antibodies in control 
and FD1-AC cells, but not in patient fibroblasts (Figure 4.8.A). Under the same 
experimental conditions, a band of about 40 kDa was seen with PCA and SHA antibodies 
in control and FD1-AC cells, but not in FD1 cells (Figure 4.8.B). This band is likely to 
represent the mature glycosylated form of the β-subunit as it disappeared when samples 
were analyzed under non-reducing conditions cells (Figure 4.8.C) which, in turn, allowed 
the detection of an additional band of about 50-55 kDa, presumably corresponding to the 
precursor form of the enzyme. As expected, both bands of 14 kDa and 40 kDa showed a 
higher intensity in AC-transduced cells than in control samples.  
 
 
Figure 4.8. Study of acid ceramidase processing in fibroblasts. Fibroblasts lysates were 
subjected to SDS-PAGE under reducing (Panel A, B and C-RC) or non-reducing conditions (Panel 
C-NRC), followed by Western blotting as described in Materials and Methods.  AC, acid 
ceramidase; C, control cells; FD1, Farber patient cells; FD1-AC, AC-transduced FD1 cells; kDa, 
kilodalton; MCA, anti-human AC monoclonal antibody; NRC, non-reducing conditions; PCA, anti-
human AC polyclonal antibody; RC, reducing conditions; SHA, anti-recombinant human AC 
antibody.  
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IV.3. IDENTIFICATION OF SECONDARY BIOCHEMICAL ALTERATIONS 
The FD1 patient is, to our best knowledge, the most severe case of Farber disease 
ever reported. With the aim to understand if sphingolipid lysosomal hydrolases are altered 
secondary to the disease and, thus, contribute to the particularly severe phenotype 
affecting this Farber case, the enzymatic activity of several enzymes was then assessed. 
 
IV.3.1. Enzymatic activity of lysosomal enzymes 
A panel of diseased cell lines was used in the study. Besides FD1 and the 
corresponding cell line transduced with AC cDNA (FD1-AC5x), fibroblasts from three other 
FD patients, two affected with subtype 1 (FD2 and FD3) and one affected with subtype 3 
(FD4), were also included. In addition, NPB cells, which are characterized by the storage 
of SM due to the deficient enzymatic activity of aSMase, NPC cells, characterized by the 
accumulation of LDL-derived free cholesterol within LE/lysosomes due to a cellular 
cholesterol trafficking defect (rev. in Vanier, 2010) and Mucolipidosis type II (MLII) cells, 
characterized by the deficiency of the enzyme N-acetylglucosamine-1-phosphotranferase 
(rev. in Lin and Pitukcheewanont, 2012) were also studied. 
Firstly, the AC enzymatic activity was reevaluated in this panel of cells (Figure 4.9). In 
agreement with previous reports (Bär et al., 2001; Kattner et al., 1997; Koch et al., 1996; 
Li et al., 1999; Medin et al., 1999), the AC enzymatic activity observed in the cells of all 
FD patients was clearly reduced when compared with control cells (Figure 4.9.A), and the 
overexpression of a functionally active AC was confirmed in transduced FD1 cells (Figure 
4.9.B). Apparently, no correlation was observed between the in vitro AC enzymatic activity 
and the disease’s severity. Indeed, the enzyme activity of FD2 and FD3 cells was found 
slightly increased than that observed in the milder form, FD4 (Figure 4.9.A). Of note, in 
NPB fibroblasts the enzyme activity was found to be reduced to about 60% of the control 
mean value (Figure 4.9.A).  
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Figure 4.9. Acid ceramidase enzymatic activity in fibroblasts. Total cell extracts were 
obtained and enzymatic activity determined as described in Materials and Methods. Each assay 
was performed in duplicate. At least 3 independent determinations were performed for each cell 
line. In parentheses is shown the number (n) of cell lines included in the study. Data is expressed 
as percent of control mean value ± SD. Control values (mean ± SD) were 3376 ± 755 nmol/h/mg 
protein. Similar values were obtained in pSV40 transformed normal fibroblasts. Cont, control 
fibroblasts; FD, Farber patients’s fibroblasts; FD-AC5x, AC-transduced Farber fibroblasts; MLII, 
Mucolipidosis type II fibroblasts; NPB, Niemann-Pick type B fibroblasts; NPC, Niemann-Pick type C 
fibroblasts. *p-value≤0.005. 
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 The enzymatic activity of aSMase (EC 3.1.4.12), -galactocerebrosidase (EC 
3.2.1.46, GalCase), -glucocerebrosidase (EC 3.2.1.45, GlcCase), total -hexosaminidase 
(EC 3.2.1.52, HexT) and -galactosidase (E.C 3.2.1.23, Glase) was then studied in FD1 
cells through specific in vitro assays using fluorogenic synthetic substrates (Table 4.1). 
 
Table 4.1. Enzymatic activity of lysosomal enzymes in fibroblast cell lysates. 
 AC aSMase GalCer GlcCer HexT Glase 
FD 
0.15 ± 0.16 
(6) 
14 ± 8 
(6) 
1.0 ± 0.2 
(6) 
83 ± 18 
(6) 
3574 ± 800 
(6) 
368 ± 68 
(6) 
NPB  
2.0 ± 0.3 
 (n=4) 
1.5 ± 1.0 
(n=4) 
ND ND ND ND 
NPC 
2.9 ± 0.3 
(3) 
12 ± 4 
(3) 
ND ND ND ND 
Control 
3.4 ± 0.8 
(n=6) 
68 ± 19 
(n=18) 
1.2 ± 0.4 
(n=6) 
197 ± 39 
(n=6) 
6255 ± 926 
(n=6) 
760 ± 127 
(n=6) 
The enzymatic activities were determined against synthetic substrates has described in Materials and 
Methods. The enzymatic activity (nmol/h/mg protein) is expressed as mean ± SD. Each assay was 
performed in duplicate; in parentheses is shown the number of separate determinations or the number 
(n) of cell lines included in the study. AC, Acid ceramidase; aSMase, Acid sphingomyelinase; FD, 
Farber patient’s fibroblasts; Glase, -galactosidase; GalCase, -galactocerebrosidase; GlcCase, -
glucocerebrosidase; HexT, total -hexosaminidase; ND, Not determined; NPB, Niemann-Pick type B 
fibroblasts; NPC, Niemann-Pick type C fibroblasts. 
 
 With the exception of the enzymatic activity of aSMase that corresponded to about 
20% of the average control value, the activity of the other lysosomal enzymes was found 
within the control range values, although for GlcCase, HexT and Glase a decreased of 
about 50% in comparison with the average control value was observed. 
 The in vitro enzymatic activity of aSMase was next evaluated in the panel of diseased 
cells included in the study using the natural radioactive substrate (choline-methyl-14C 
sphingomyelin) (Figure 4.10). 
The enzymatic activity of aSMase was found surprisingly low in FD1 cells and 
comparable to that observed in MLII cells. It corresponded to about 25% of the average 
control value, which was slightly higher than observed with the synthetic substrate 
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reflecting, probably, the higher affinity of the enzyme against the natural substrate. 
However, a similar reduction was not found in the other FD cells. Moreover, AC 
overexpression did not correct the enzyme deficiency. As expected, the deficient aSMase 
enzymatic activity was confirmed in NPB cells. Of note, the residual enzymatic activity of 
aSMase found in the culture medium of FD1 cells was comparable to the one observed in 
the culture medium of control cells (data not shown), suggesting that the enzyme 
produced by FD1 cells is not preferentially secreted.  
 
 
Figure 4.10. Acid sphingomyelinase enzymatic activity in fibroblasts. Total cell 
extracts were obtained and enzymatic activity determined against choline-methyl-14C 
sphingomyelin as described in Materials and Methods. Each assay was performed in duplicate. At 
least 3 independent determinations were performed for each cell line. In parentheses is shown the 
number (n) of cell lines included in the study. Data is expressed as percent of control mean value ± 
SD. Control values (mean ± SD) were 107 ± 29 nmol/h/mg protein. Similar values were obtained in 
pSV40 transformed normal fibroblasts. Cont, control fibroblasts; FD, Farber patients’s fibroblasts; 
FD-AC5x, AC-transduced Farber fibroblasts; MLII, Mucolipidosis type II fibroblasts; NPB, Niemann-
Pick type B fibroblasts. *p-value≤0.00001. 
 
As one possible explanation for the partial enzymatic deficiency of aSMase observed 
in FD1 cells would be the existence of deleterious defects in the gene coding for human 
aSMase, mutational analysis in SMPD1 gene was then carried out. 
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IV.3.2. Mutational screening in SMPD1 gene 
SMPD1 genomic and cDNA from FD1 patient’s fibroblasts were analyzed for the 
presence of mutations. To that end, PCR products corresponding to each of the 6 exons 
of the SMPD1 gene and the corresponding intronic flanking sequences were subjected to 
sequence analysis. In addition, PCR products obtained from the amplification of five 
overlapping cDNA/SMPD1 fragments were also sequenced (Figure 4.11). However, no 
putative pathogenic alterations were found in either SMPD1 genomic DNA or full length 
cDNA. 
 
 
Figure 4.11. Mutational screening in SMPD1 gene. A. Schematic representation of the 
SMPD1 gene. B. Amplification strategy of cDNA/SMPD1 in five overlapping fragments. F, 
fragment. 
 
We then questioned if the level of mRNA/SMPD1 would be reduced in FD1 cells. 
Therefore, semi-quantitative analysis of the transcript was performed (Figure 4.12). 
 
 
Figure 4.12. Semi-quantitative analysis of cDNA/SMPD1. For expression normalization, 
ABCD1 was used as endogenous gene and the RT-PCR exponential phase was considered at 25 
cycles for both genes. The expression level referred to as the ratio of SMPD1/ABCD1 is shown 
below each lane. ABCD1, Gene coding for adrenoleukodystrophy protein; bp, base pairs; C, 
Control; FD1, Farber disease patient 1; SMPD1, Acid sphingomyelinase gene. 
 
15’ 3’2 3 4 5 6
F1
F2
F3
F4
F5
B.
A.
1          2         5         10        1        2         5         10 /µL
1.3      1.7       1.5       1.4      0.6     0.7      0.6       0.7      SMPD1 / ABCD1
SMPD1
ABCD1
C FD1
1000
750
500
400
bp
Results  
 64 
In FD1 patient’s cells, a decreased level of mRNA/SMPD1 of at least 50% when 
compared with control cells was observed, thus suggesting that the partial enzymatic 
deficiency observed for the aSMase can be explained, at least in part, by negative 
modulation of the transcription of the gene. However, its exact mechanism is presently 
unclear. 
In order to understand if the reduced aSMase enzymatic activity observed in FD1 
cells would have any impact in the level of total cell SM, the level of two structurally closed 
and metabolic linked SLs, SM and Cer, was then assessed in fibroblasts.   
 
IV.3.3. Sphingolipid analysis in fibroblasts 
In all four FD fibroblast lysates, the level of total Cer and SM was determined (Figure 
4.13.A) and data analyzed in terms of the ratio value SM/Cer (Figure 4.13.B). In NPB 
cells, in addition to the increased level of total SM, a higher level of total Cer compared 
with the average level in control cells was observed. Of note, the average level of the SM 
to Cer ratio was only slightly increased when compared to control cells. In FD1 case the 
increased level of Cer was confirmed and the level of SM found in the lower range of 
control values. The SM/Cer, which was considerably reduced when compared with control 
cells, was corrected by the overexpression of AC. In fibroblasts from a milder FD case, 
FD4, the level of SM approximated that of control cells and the SM/Cer was about 2-fold 
higher than in the neonatal FD1 case. In FD2 and FD3 cases, corresponding to a lesser 
severe form of the disease than FD1, the level of Cer was slightly higher than in FD1 cells. 
These findings are in agreement with the notion that the clinical phenotype is not 
correlated with the level of stored Cer (Bär et al., 2001; van Echten-Deckert et al., 1997). 
In NPC cells no alterations were noticed regarding to either Cer and SM levels, or the ratio 
value (data not shown).  
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Figure 4.13. Ceramide and sphingomyelin levels in fibroblasts. Lipids were extracted 
and quantified as described in the Materials and Methods. Each assay was performed in duplicate. 
At least 3 independent determinations were performed for each cell line. Similar values to control 
cells were obtained in pSV40 transformed control fibroblasts. Data is expressed as percent of 
control mean value ± SD. Control values for ceramide (A), sphingomyelin (A) and SM/Cer ratio (B) 
were 1350 ± 292 pmol/mg, 26900 ± 5859 pmol/mg and 19.4 ± 4.0, respectively. Cer, Ceramide; 
Cont, control fibroblasts; FD, Farber patients’s fibroblasts; FD-AC, AC-transduced FD fibroblasts 
(5x- or 10x-infected cells); NPB, Niemann-Pick type B fibroblasts; SM, Sphingomyelin. 
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Based on the fact that neither the amount of accumulated Cer nor residual AC activity 
in FD fibroblasts was apparently correlated with the disease onset and progression, and in 
cells from FD1 patient, representing the most severe form of the disease, significant 
alterations were found for either the enzymatic activity of aSMase or the ratio value of total 
Cer for total SM, the relation between these two variables were then analyzed (Figure 
4.14).    
 
Figure 4.14. Analysis of the ratio of total cellular sphingomyelin and ceramide vs. 
aSMase enzymatic activity. Fibroblast cells were used for lipids analysis and enzymatic 
assays according to the procedures described in Materials and Methods.  For each case, the mean 
value was referred as percentage of the control mean value. aSMase, Acid sphingomyelinase; Cer, 
Ceramide; Control cells (♦); FD, Farber patients’s cells (■); FD-AC,  AC-transduced FD cells (5x- 
or 10x-infected cells, ▲). For each case, the mean value was referred as percentage of the control 
mean value. 
 
The ratio value SM/Cer clearly discriminated controls from FD cells, whereas the 
enzymatic activity of aSMase allowed, apparently, the differentiation between the neonatal 
(FD1 case), subtype 1 (FD2 and FD3 cases) and subtype 3 (FD4 cases) phenotypes. 
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Farber disease or Farber's lipogranulomatosis (FD, MIM 228000) is a recessively 
inherited sphingolipid (SL) storage disorder caused by the deficiency of AC that leads to 
the intralysosomal accumulation of ceramide. Typical symptoms, generally noticed early in 
life, include the unique triad of subcutaneous nodules, painful and progressively deformed 
joints, and hoarseness by laryngeal involvement. Based on the age of onset, the severity 
of symptoms, and the difference in organ affection by ceramide storage, seven disease 
subtypes are distinguished (Moser et al., 2001). Subtypes 1 to 6 are associated with the 
deficiency of AC caused by mutations in the ASAH1 gene, whereas subtype 7 is caused 
by the deficiency of the SAP precursor, prosaposin. Except for subtype 7, the most severe 
form is subtype 4, a rare neonatal form of the disease described to date in only about 7 
patients (Antonarakis et al., 1984; Qualman et al., 1987; Nowaczyk et al., 1996; Willis et 
al., 2008). 
 Although 80 patients with the diagnosis of FD are referred in the literature (Levade et 
al., 2009; Moser et al., 2001), the genotype was characterized thus far in only 20 patients 
leading to the identification of 23 mutations in the ASAH1 gene, mostly missense 
mutations (17/23) and associated with the subtypes 1 and 3 of the disease (Al Jasmin, 
2012; Bär et al., 2001; Chedrawi et al., 2012; Cvitanovic-Sojat et al., 2011; Devi et al., 
2006; Koch et al.,1996; Kostik et al., 2013; Levade et al., 2009; Li et al., 1999; Muramatsu 
et al., 2002; Muranjan et al., 2011; Zhang et al., 2000). Thus, comparing with other 
lysosomal diseases few causative mutations of FD are known, and for the vast majority of 
them the molecular mechanism is unclear. More recently, mutations in this gene have also 
been reported in patients with spinal muscular atrophy with progressive myoclonic 
epilepsy (MIM 159950) (Zhou et al., 2012), suggesting that Farber disease may be widely 
underestimated. Aiming to contribute to extend the information in this particular field, 
cultured skin fibroblasts from a neonatal FD patient presenting the most severe clinical 
manifestations of AC-deficiency ever described (Kattner et al., 1997; Schäfer et al., 1996) 
were studied by integrating data from DNA, RNA, protein and SL analysis. 
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V.1. ELUCIDATION OF THE PRIMARY DEFECTS IN THE NEONATAL FORM 
OF FARBER DISEASE 
 In this work, the genotyping of the first, and to our knowledge the only, reported FD 
case with non-immune hydrops revealed a compound heterozygous carrying two novel 
mutations: g.24491A>G (c.917+4A>G), in intron 11 and the large deletion 
g.8728_18197del (c.126-3941_382+1358del), encompassing exons 3 to 5 of ASAH1 
gene. The transition in the 5’ss consensus sequence of intron 11 represents the third 
report of a splicing mutation in the ASAH1 gene (c.457+4A>G associated with the 
disease’s subtype 1 and 5 (Muranjan et al., 2011), c.1098+1G>T with subtype 5 (Bär et 
al., 2001) and present study). The second mutation is the first, and to our best knowledge 
the only, gross deletion reported in the ASAH1 gene.  
 Based on data reported herein, FD cases with mutation(s) detected in only one allele 
on the conventional analysis of just ASAH1 genomic DNA must be examined for the 
presence of a large heterozygous deletion in the second allele. Without direct cDNA 
analysis, this kind of mutations can remain unidentified. In the literature, at least 3 FD 
patients represent possible candidates for the presence of a large deletion in the second 
allele (Al Jasmi, 2011; Bär et al., 2001; Muranjan et al., 2011). 
 The precise ascertainment of the genotype is important for a correct establishment of 
genotype-phenotype correlations and, subsequently, for genetic counseling of patients 
and families with this specific rare disease. In this regard, experimental and in silico data 
analysis presented in this study clearly demonstrate that these two novel mutations result 
in null alleles, thus explaining the disease’s clinical severity of this compound 
heterozygous FD case. The primary transcript generated by the allele carrying the splicing 
mutation is likely to be prematurely degraded as no detectable transcripts were seen after 
cDNA amplification. For the other allele, the main identified transcript lacked the entire 
sequences of exons 3 to 5, predicting the production of a truncated polypeptide with only 
52 amino acids, of which 42 correspond to the wild-type N-terminal primary sequence of 
AC. No detectable molecular forms corresponding to precursor or proteolytically 
processed mature protein were observed. Thus, if this aberrant transcript escapes to 
degradation by the nonsense-mediated mRNA decay mechanism (Chang et al., 2007) 
and is translated, then the mutant polypeptide must be prematurely degraded. In 
compliance with these findings, the in vitro residual enzymatic activity observed in 
patient's cells (Kattner et al., 1997) represents one of the lowest values reported for FD 
patients (Levade et al., 2009).  
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 The presence of two loss-of-function mutations in the rare neonatal form of FD, as 
demonstrated in this work, indicates that the last step of the SL degradation pathway must 
be deeply blocked due to the absence of any functionally active AC. Therefore, patient’s 
cells represent an attractive cellular model to explore downstream effects of lysosomal 
AC-deficiency, especially if considering that the murine knock-out model was found not 
viable (Li et al., 2002). However, very recently, after the conclusion of the experimental 
part of the work described in this thesis, the first viable animal model of systemic AC 
deficiency was reported (Alayoubi et al., 2013). This mouse model harboring a single 
nucleotide mutation in ASAH1 gene showed characteristic features of FD, including 
growth retardation and early death, reduced enzyme activities, accumulation of ceramide, 
abnormal infiltrations with foamy macrophages in various tissues, and the presence of 
Farber bodies by electron microscopy. Furthermore, lentivector-mediated neonatal gene 
delivery of human ASAH1 / cDNA partially corrected the disease manifestations. This new 
animal model of AC deficiency is particularly valuable not only to future studies on 
pathophysiology of FD, namely, the effects of ceramide storage in different tissues and 
organ environments, but also to study SLs metabolism.  
 
V.2. IDENTIFICATION OF SECONDARY BIOCHEMICAL ALTERATIONS 
 In all cells of FD patients enrolled in this study, the deficient enzymatic activity of AC 
was confirmed. Moreover, in cells overexpressing AC a substantially increased of the 
enzymatic activity was observed, as previously reported (Medin et al., 1999). 
 Previous studies suggested the importance of a balanced level of several lysosomal 
enzymes in the maintenance of cellular ceramide levels, namely various 
sphingomyelinases and ceramidases (Ferlinz et al., 2001), and also the possibility that AC 
could be part of a multienzymatic complex, integrating acid sphingomyelinase (aSMase) 
and -galactosidase but not several other lysosomal enzymes (He et al., 2003).  
 The measurement of the in vitro enzymatic activity of several lysosomal enzymes in 
fibroblasts from the neonatal FD case showed that, in addition to the enzymatic deficiency 
of AC, a decrease of about 25% in the enzymatic activity of aSMase was also observed, 
while for the other lysosomal enzymes (-galactocerebrosidase,-glucocerebrosidase,  
total -hexosaminidase and-galactosidase) the values were comparable to normal cells. 
As expected, in fibroblasts of patients affected with MLII or NPB, a similar decrease of 
aSMase enzymatic activity was observed. In MLII, the enzymatic deficiency of N-
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acetylglucosamine-1-phosphotranferase prevents the acquisition of the M6P marker by 
lysosomal soluble proteins resulting in its preferential secretion (rev. in Lin and 
Pitukcheewanont, 2012). In NPA and NPB the primary defect is the enzymatic deficiency 
of aSMase caused by mutations in the SMPD1, but the enzymatic deficiency is generally 
more severe in NPA than in NPB. In NPC, most of patients have mutations in NPC1 gene 
and mutant cells show reduced ability to esterify cholesterol after loading with 
exogenously derived LDL-cholesterol. As NPC is characterized by a secondary reduction 
of aSMase enzymatic activity, all three types are considered forms of the same disease 
(rev. in Vanier, 2010). Apparently, the reduced aSMase enzymatic activity observed in the 
neonatal FD cells was not warranted by the presence of putative pathogenic genetic 
alterations in the gene coding for the human aSMase, the SMPD1 gene. However, an 
alteration in the level of mRNA/SMPD1 to about 50% of control suggests the negative 
modulation of the SMPD1 gene at the transcriptional level. The reason for this observation 
is presently unclear. Recent bioinformatics and functional data propose the existence of 
the CLEAR gene network and the TFEB as master regulator of lysosomal biogenesis 
(Sardiello et al., 2009). Interestingly, ASAH1, but not SMPD1, is a target gene of TFEB 
(Palmieri M et al., 2011). It is, therefore, possible that transcription of the SMPD1 gene 
may be regulated by other transcription factors and/or by a distinct transcriptional 
mechanism. 
 In this regard, it is important to underline that the SMPD1 gene is within an imprinted 
region of the human genome (Simonaro et al., 2006) and the implication of this 
observation warrants further investigation in the future. Another interesting finding was the 
statistically significant decreased of the enzymatic activity of AC in NPB fibroblasts. In this 
disease the disruption of the SL catabolic pathway is located one step upstream of that 
catalysed by the AC. The secondary partial enzymatic deficiency observed in FD and 
NPB, aSMase and AC, respectively, supports the notion that these enzymes may, indeed, 
interact in vivo as previously suggested (He et al., 2003).  As consequence, the aSMase 
downregulation observed in cells from the neonatal FD case may represent a 
compensatory cell mechanism resulting from the inexistence of any functionally active AC. 
As a matter of fact, for the other FD cell lines included in this study which represent 
disease’s subtypes 1 and 3, the activity of aSMase was not found particularly reduced in 
comparison with control cells, but otherwise their clinical phenotype is not as severe as in 
the neonatal FD case. A similar observation had been previously reported by other 
authors (van Echten-Deckert et al., 1997) who included in the study fibroblasts of several 
FD patients, the most severe one with onset at 3 months and death at 6 months. Based in 
these observations, it would be plausible to consider that the inhibition of aSMase 
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enzymatic activity by ceramide occurs only when this metabolite attains a substantially 
high concentration thus, justifying the data obtained in cells from the neonatal FD patient. 
However, overexpression of AC did not correct for the partial enzymatic deficiency of 
aSMase observed in non-transduced FD cells. Even so, as the neonatal form here studied 
represents a unique cell model due to the extensive, or even total, blockage of the last 
step of the lysosomal SL catabolic pathway, the intracellular level of two structurally close 
and metabolically linked SLs, Cer and SM, were determined and reanalysed.  
 As expected, in FD and NPB cells the level of total Cer and SM was significantly 
increased with respect to control cells, respectively. The AC overexpression corrected the 
ceramide storage observed in cells from the neonatal form as previously reported (Medin 
et al., 1999). Moreover, an increased level of total Cer was observed in NPB cells. This 
observation is in accordance with the partial enzymatic deficiency of AC observed in these 
cells. In the neonatal FD cells, the enzymatic activity observed for aSMase which 
corresponded to about 25% of the average control activity, would predict an increased 
level of total SM. Surprisingly, a reduced level of total cell SM to about 50% was observed 
when compared with the average level of control cells. In both cases, the difference with 
respect to control cells was not statistically significant, although it was close to the 
significance level of 0.05. However, it must be noted that the assay used in lipid 
quantitation introduced small variations and the state of the cell culture, i.e. degree of cell 
confluency and passage number, may also have contributed with additional variations.  
 SL data was also analyzed in terms of the total level of SM vs. Cer. This ratio was 
significantly decreased in all FD cells, particularly in the neonatal form (subtype 4), 
representing less than 15% of the average control value. However, an inverse proportion, 
i.e. a significant increase of the ratio SM/Cer, was not seen in NPB cells. Thus, the 
imbalance of total SM to total Cer observed in FD fibroblasts is likely to be due not only to 
the abnormally high level of total Cer but also to a slightly decreased level of total SM.  Of 
note, the overexpression of AC normalized the ratio observed for the total level of SM and 
Cer, strongly suggesting that specific steps of the complex network of metabolic reactions 
located downstream of lysosomal sphingosine (Sph) are under tight regulation. As a 
matter of fact, in the neonatal FD cells, the level of lysosomal Sph is likely to be 
dramatically unbalanced, conditioning the downstream synthesis of Cer and therefore the 
level of Cer (from the salvage pathway) that is returned to the cell metabolism, namely for 
the SM synthesis at the GC. This would explain, at least in part, why the level of total SM 
is reduced in fibroblasts from neonatal FD patient.  
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 As already mentioned above, in NPA and NPB, the disruption of the SL catabolic 
pathway is located one step upstream of that catalysed by the AC. Altogether, these 
findings suggest that a yet unknown balancing mechanism(s) is altered in NPB fibroblasts 
and, apparently, blocked in FD. A deep unbalanced level of Cer to SM, as observed in FD 
fibroblasts, would contribute to the alteration of biophysical properties of membranes and 
explain the disease symptoms. Therefore, the impairment of AC enzymatic activity is likely 
to be more dramatic for the cell to keep the balance level of the two bioactive SLs, Cer 
and SM, than the deficiency in the enzymatic activity of aSMase, thus justifying the 
disease’s severity of the Farber case. As the steady state level of cell Cer and SM result 
from a complex network of reactions in which AC and aSMase also participate, further 
studies must be carried out to evaluate other metabolic points of this intricate cell network. 
 In agreement with other studies (van Echten-Deckert et al., 1997), data here report 
support the notion that the severity of the FD clinical phenotype is neither correlated with 
the AC residual enzymatic activity nor the level of total Cer. Nevertheless, some 
controversy still exists regarding to this issue (Chatelut et al., 1996; van Echten-Deckert et 
al., 1997; Levade et al., 1995b; present study). Therefore, data reported herein was also 
analyzed in terms of the ratio value SM/Cer vs. the enzymatic activity of aSMase. Controls 
were clearly distinguished by FD patients through the ratio value of SM/Cer, and the 
clinical phenotypes of the FD patients enrolled in this study, i.e. subtypes 4, 1 and 3, were, 
apparently, discriminated by the enzymatic activity of aSMase. This preliminary data 
suggest that aSMase can be regarded as a potential disease biomarker. However, the 
number of patients enrolled in this study was too small to draw definitive conclusions and, 
therefore, this analysis must be extended, in future, to more FD patients.   
 Finally, in view of the findings here reported, an accurate assessment of the level of 
SLs seems to be helpful in detecting secondary imbalances in the cellular content and 
distribution of these lipid molecules, including GSLs, which might be informative for the 
disease progression. Moreover, it is also important to note that as FD is considered a very 
rare storage disorder, the enzymatic assay of AC may be excluded from the panel of 
biochemical enzymatic assays used in the diagnosis of LSDs. Moreover, typical clinical 
signs of the disease may not be present in neonatal forms. In this regard, this work 
highlights the importance to consider the biochemical study of FD in those cases 
presenting a decreased aSMase enzymatic activity but in which Niemann-Pick disease 
(types A, B and C) and MLII have been biochemically ruled out. 
 In conclusion, in this work the mutations underlying the neonatal form of FD were 
described for the first time, two novel null alleles identified and the first gross deletion in 
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the ASAH1 gene reported, which not only broad the spectrum of disease-causing 
mutations and enlarge the knowledge on the molecular mechanisms of FD, but they also 
contributed for the accuracy of disease’s molecular diagnosis. Additionally, data described 
herein also give strength to the hypothesis that AC and aSMase may, indeed, interact in 
vivo and report for the first time alterations in the total level of Cer vs. SM that are likely to 
have important pathophysiological implications to FD. Nevertheless, a more profound 
characterization of the basic properties of AC, the nature of AC-aSMase interaction, and 
other possible interaction partners, and the downstream consequences of the AC 
deficiency, namely at the level and cell distribution of SL and GSL molecules, represent 
key points that must be addressed in future works to improve our understanding about AC 
cell biology in normal and disease conditions.   
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Farber disease, also known as Farber's lipogranulomatosis, is a clinically heterogeneous autosomal recessive
disease caused by mutations in the ASAH1 gene. This gene codes for acid ceramidase, a lysosomal
heterodimeric enzyme that hydrolyzes ceramide into sphingosine and fatty acid. To date, less than 25 distinct
mutations have been identified in Farber patients, but no large deletions have yet been reported. In this work,
cultured fibroblasts from a Farber patient with the rare neonatal form of Farber disease were studied to elu-
cidate the molecular basis of this extremely severe phenotype. Direct sequencing of ASAH1 genomic DNA re-
vealed the causative heterozygous mutation in the donor splice site consensus sequence of intron 11,
g.24491A > G (c.917 + 4A > G), that resulted in the absence of detectable mRNA. Subsequent analysis of
ASAH1mRNA showed total skipping of exons 3 to 5. Long-range PCR and sequencing led to the identification
of a gross deletion of ASAH1 gene, g.8728_18197del (c.126-3941_382 + 1358del) predicting the synthesis of
a truncated polypeptide, p.Tyr42_Leu127delinsArgfs*10. Accordingly, no molecular forms corresponding to
precursor or proteolytically processed mature protein were observed. These findings indicate that any func-
tionally active acid ceramidase is absent in patient cells, underscoring the severity of the clinical phenotype.
Molecular findings in the non-consanguineous parents confirmed the compound heterozygous ASAH1 geno-
type identified in this Farber case. This work unravels for the first time the mutations underlying the neonatal
form of Farber disease and represents the first report of a large deletion identified in the ASAH1 gene. Screen-
ing for gross deletions in other patients in whom the mutation present in the second allele had not yet been
identified is required to elucidate further its overall contribution for the molecular pathogenesis of this dev-
astating disease.
© 2013 Elsevier Inc. All rights reserved.
1. Introduction
Acid ceramidase (N-acylsphingosine amidohydrolase, AC, EC
3.5.1.23) is a soluble N-glycoprotein that catalyzes the lysosomal
degradation of ceramide to sphingosine and fatty acid [1]. Human
AC is synthesized in precursor form of 53–55 kDa and transported
to the lysosome via the mannose-6-phosphate pathway [2]. In late
endosomes/lysosomes, the precursor is autoproteolytically processed
to the non-glycosylated α-subunit (13 kDa) and the glycosylated
β-subunit (40 kDa) that remain interlinked by a disulfide bridge at
Cys143 [3,4]. AC is encoded by the ASAH1 gene that spans about
30 kb on chromosome 8p21.3-p22 and comprises 14 exons and 13
introns. An open reading frame of 1185-bp corresponds to a primary
translation product of 395 amino acids [5,6].
The deficiency of AC activity leads to the recessively inherited sphin-
golipid storage disorder, Farber disease or Farber's lipogranulomatosis
(FD, MIM 228000). Typical symptoms, generally noticed early in life,
include the unique triad of subcutaneous nodules, painful and progres-
sively deformed joints, and hoarseness by laryngeal involvement. Based
on the age of onset, the severity of symptoms, and the difference in
organ affection by ceramide storage, seven disease subtypes are dis-
tinguished [7]. Subtypes 1 to 6 are associated with the deficiency of
AC caused bymutations in the ASAH1 gene, whereas subtype 7 is caused
by the deficiency of the sphingolipid activator protein precursor,
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prosaposin. Except for subtype 7, the most severe form is subtype 4, a
rare neonatal form of the disease with death occurring before 1 year
of age [8–10].
Although 80 patients with the diagnosis of FD are referred in the
literature [7,11], the genotype was characterized thus far in only 20
patients leading to the identification of 23 mutations in the ASAH1
gene, mostly missense mutations (17/23) [5,6,11–20]. Comparing
with other lysosomal diseases few causative mutations of FD are
known, and for the vast majority of them the molecular mechanism
is unclear. More recently mutations in this gene have also been
reported in patients with spinal muscular atrophy with progressive
myoclonic epilepsy (MIM 159950) [21]. Farber disease may be, thus,
widely underestimated.
The present case, to our knowledge, had the most severe clinical
manifestation of AC-deficient FD ever described [22,23]. In this
work, the patient's genotype was elucidated and the molecular mech-
anisms of identified recessive mutations evaluated by studying their
impact on the protein function and disease's clinical severity.
2. Materials and methods
2.1. Patient's clinical and biochemical data
The patient is the first, and to our knowledge the only, reported FD
case with non-immune hydrops fetalis [22,23]. Briefly, the female pa-
tient presented a severe, generalized edema and extreme enlarge-
ment of her liver and spleen. Massive histiocytic infiltration was
observed in liver, spleen, bonemarrow, lymph nodes, thymus, parotid
gland and adrenal medulla. The child died 3 days after birth from dis-
seminated intravascular coagulation. The diagnosis of FD, subtype 4,
was based on the deficient enzymatic activity of AC [23] and accumu-
lation of ceramide in cultured fibroblasts [24] and visceral organs
[22].
2.2. Cell lines and cell culture
Skin fibroblasts from control individuals were maintained anony-
mous throughout the study. Normal controls andNiemann–Pickdisease
(NPD) type B, kindly provided by Dr. Lúcia Lacerda, Centre Medical
Genetics (Oporto, Portugal), GM2315 (subtype 3, with onset at 2 years
and death at 30 years of age) obtained from Coriell Institute for Medical
Research Cell Line Repository (New Jersey, USA), mock-infected fibro-
blasts of FD patient and the corresponding cell line transduced with
AC cDNA (FD-AC, [25]), were grown to confluency in Dulbecco's Modi-
fied Eagle Medium (Gibco), supplemented with 10% of fetal calf serum
and antibiotics, at 37 °C in an atmosphere containing 5% CO2. After
trypsinization the cells were washed with cold phosphate buffered-
saline and the pellet was frozen at−20 °C or immediately processed.
2.3. Antibodies
Anti-AC mouse monoclonal antibody raised against the peptide
segment 88–182 of the human protein (MCA) was from BD Transduc-
tion Laboratories (BD Bioscience). Anti-AC goat polyclonal antibody
produced against an internal segment of the human protein (PCA) was
from Santa Cruz Biotechnology. Rabbit polyclonal anti-AC antibody
(SHA) was kindly provided by Prof. Konrad Sandhoff (Life and Medical
Sciences Institute, University of Bonn, Germany). Anti-mouse and anti-
rabbit secondary antibodies were from Cell Signalling. Anti-goat sec-
ondary antibody was from Santa Cruz Biotechnology.
2.4. Mutation screening in genomic DNA
Genomic DNA was extracted from skin fibroblasts with “EZ1 DNA
Tissue kit” on BioRobot EZ1 (Qiagen), according to manufacturer's
instructions. Genomic fragments (between 223 and 613 bp), mostly
encompassing each exon and the corresponding flanking sequence,
were amplified using twelve designed primer sets (available on re-
quest). Polymerase chain reaction (PCR) amplificationswere performed
in a total reaction volume of 25 μl using about 100 ng of genomic
DNA, 1x PCR ImmoMix™ Red (Bioline) and 0.25 μM of each primer,
for 35 cycles at specific annealing temperatures. After agarose gel
electrophoresis, PCR products were purified with ExoSap-IT (GE
Healthcare) according to the manufacturer's instructions and se-
quenced in forward and reverse directions with BigDye Direct Cycle
Sequencing Kit (Applied Biosystems) on an ABI Prism 310 automatic
sequencer (Applied Biosystems). Raw data was analyzed with the
sequence analysis software FINCH TV (Geopiza) version 1.4.0. Com-
parative sequence analysis was performed using the Ensembl genome
server. Each candidate mutation was confirmed in two independent
PCR and sequencing reactions.
2.5. Long-range PCR and sequencing
Long-range PCR was performed using the Expand Long Template
PCR System (Roche, Applied Science) according to manufacturer's
instructions. The specific set of primers used to amplify the target ge-
nomic region of theASAH1 genewas 5′ CAGACTTGATGTTGTCTTCACA-3′
(intron 2) and 5′-CTGAAATTTGGGCTTGCTATG-3′ (intron 6). The
amplified fragment of 11329 bp corresponds to the nucleotides 8371–
19699 of the ASAH1 transcript sequence ENST00000262097. After
preheating of 94 °C for 2 min, samples were subjected to 30 cycles of
denaturation at 94 °C for 10 s, annealing at 54 °C for 30 s, and primer
extension at 68 °C for 8 min. In the last 20 cycles, successive increments
of 20 s were applied to the extension time. The final extension was
completed by 8 min at 68 °C. After electrophoresis on a 2% agarose gel,
the long-range PCR fragmentwas purifiedwith ExoSap-IT and sequenced
on an ABI Prism 310 automatic sequencer (Applied Biosystems). The
mutation was confirmed by repeat PCR and sequencing.
2.6. ASAH1 transcript analysis
Total RNA was isolated from skin fibroblasts using the High Pure
RNA Isolation Kit (Roche Applied Science). First-strand cDNA was
synthesized using the Ready-To-Go™ You-Prime First-Strand Beads
(GE Healthcare), according to the manufacturer's instructions. The
full length cDNA was amplified using specific forward and reverse
primers at an annealing temperature of 58 °C, F1-5′-GGCTGCTAGA
GCGATGCCG-3′ and R1-5′-CTTGTATAGGT TGGTGAGCA-3′, and the
PCR fragment subjected to sequence analysis using the reference
sequence from the Ensembl genome database ENST00000262097.
Alternatively, cDNA was amplified using previously reported primers
[12]. In semi-quantitative studies, a fragment encompassing exons
8–14 was amplified in 25-cycles PCR reaction using specific primers,
F3-5′-TTGGAGTATTTCTTGGGTGG-3′ and R3-5′-CGGCAGGTTCTCTT
TGAGTC-3′, and analyzed by agarose gel electrophoresis using
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as endogenous
reference gene. Comparative analysis was performed using ImajeJ
software (version 1.6.0).
2.7. Bioinformatic analysis
Alignments of the nucleotide sequences of the mutant and normal
alleles were achieved using the Ensembl genome server. The web tool
Human Splicing Finder [26], version 2.4.1, was used to predict the
strength of 5′ splice junctions in the ASAH1 gene, and potential
branch points, splicing enhancers and splicing silencers motifs. Splice
prediction by using consensus sequences was also performed with
softwares SpliceView and MaxEnt [27]. The nucleotide sequences of
the ASAH1 gene were screened for the presence of repetitive elements
using the default settings of the RepeatMasker software, version
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open-4.0.1. The sequence was also analyzed with the non-B DNA
motif search tool, version 2.0 [28].
2.8. Protein analysis by Western Blot
Cell pellets from cultured fibroblasts were suspended in 1× lysis
buffer (Cell Signalling), 1 mM phenylmethanesulfonylfluoride and
protein inhibitor cocktail (Roche), lysed by sonication on ice, followed
by a 10 min centrifugation at 13200 g at 4 °C. Under reducing condi-
tions, the samples were prepared with Laemmli sample buffer and
0.1 M dithiothreitol. After heat denaturation, approximately 50 μg of
protein was electrophoresed on 10% acrylamide gel and transferred
to nitrocellulose membrane (Amersham Biosciences). The membrane
was incubated in blocking buffer (1× Tris-buffered saline, 0.1%
Tween-20 and 5% dried non-fat milk) for 2 h, and incubated overnight
at 4 °C with primary antibody (diluted in blocking buffer). Immunore-
activity was visualized with horseradish-peroxidase-conjugated sec-
ondary antibody followed by chemiluminescence detection (Luminata
Western HRP Substrates, Millipore).
2.9. Lipid assays
For ceramide quantification, lipids were extracted and ceramide
mass measured as previously reported using Escherichia coli mem-
branes as a source of diacylglycerol kinase [29,30]. Radioactive
ceramide-1-phosphate was isolated by thin layer chromatography
(TLC) (Whatman LK6D plates) using chloroform/acetone/methanol/
acetic acid/water (50:20:15:10:5, v/v/v/v/v). TLC plates were exposed
to X-ray films. Then, lipid spots were scraped, and phosphorylated
ceramide and diacylglycerol were counted by liquid scintillation.
Sphingomyelin was quantified by analysis of lipid phosphorus after
alkaline methanolysis as previously described [31].
3. Results
3.1. The intronic sequence variation c.917 + 4A > G
The genomic DNA was screened for pathogenic mutations in the
ASAH1 gene. The transition g.24491A > G (c.917 + 4A > G) in intron
11 was found in heterozygosity (Fig. 1). This mutation was not
detected in 100 normal control chromosomes. No other predicted
deleterious alteration was found in exons and flanking intron se-
quences of the patient's sample. In accordance with patient's geno-
type, the mother was heterozygous for the same gene defect. The
father's sequence was normal in this region (data not shown). Since
this is a novel mutation, functional studies would be needed to ascer-
tain its pathogenicity. Thus, in silico analysis of this mutation was
performed. In exon 11/intron 11 splice junction two possible donor
splice sites crossing the mutation were recognized by the web tools
SpliceView, Human Splicing Finder and MaxEnt model. The higher
the score, the higher is the probability that the sequence is a true
splice site. Considering that the highest scored sequence, TGAgtaagt,
is the true splice site, then the mutation c.917 + 4A > G occurs 4
nucleotides downstream of the first position of intron 11. Ideal MaxEnt
splice site score for 5′ss is 11.81. For the mutation c.917 + 4A > G,
MaxEnt model estimated the reduction of the 5´ss strength from 8.82
to 3.27 (average score for the donor splice site in the ASAH1 gene:
8.83). Furthermore, in addition to the splice site, intronic and exonic
cis-elements play also an important role in splicing. For the mutation
c.917 + 4A > G in intron 11, Human Splicing Finder software predicts
the disruption of one exonic splicing enhancer motif for the protein
SRp5, and the creation of one exonic splicing enhancer motif for
the protein SRp40. Moreover, the creation of one potential splicing
silencer motif ([T/G]G[T/A]GGGG) in two positions of the splicing
junction sequence, and the creation of three potential exonic splicing
silencers-hexamers upstream of the transition were also noticed.
These findings further support the disruption of the normal splicing
process by the mutation c.917 + 4A > G.
3.2. Sequencing of ASAH1 transcripts
Since the study of genomic DNA allowed the identification of only
one mutant allele, cDNA/ASAH1 sequencing studies were then carried
out. Agarose gel electrophoresis of the amplified full-length cDNA
fragment obtained from skin fibroblasts-derived total RNA showed a
major faster migrating band than the wild type fragment (Fig. 2A).
Sequence analysis revealed the skipping of the full sequences of
exons 3 to 5 (Fig. 2B). This alteration was not detected in 100 normal
control chromosomes. In addition, several other faster migrating
bands were observed (data not shown). They are likely to represent
shorter transcripts that may have resulted from alternative splicing,
which process is often over-represented when mutations interfere
with the cell splicing machinery [32]. In accordance with patient's
genotype, the father was heterozygous for the exon-skipping defect.
The mother's sequence was normal in this region (data not shown).
3.3. Breakpoint characterization of ASAH1 exons 3–5 deletion
As the patient was heteroallelic for the c.917 + 4A > G mutation
and cDNA analysis revealed a fragment lacking the full-sequences of
exons 3 to 5, the existence of a large deletion in the ASAH1 gene
was postulated. To investigate this hypothesis, a long-range PCR
was designed to amplify ASAH1 genomic DNA encompassing exons
2 to 6. After agarose gel electrophoresis, two fragments were observed
in patient's sample: the normal amplicon and a shorter fragment that
was over-represented probably due to the more efficient amplification
of shorter fragments often observed in long PCR analysis (Fig. 3B).
Fig. 1. Identification of the mutations c.917 + 4A > G in the ASAH1 gene. Cycle
sequencing of the PCR products obtained from genomic DNA of patient's cells was
performed as described in Materials and methods. The region of the electropherogram
encompassing the exon 11/intron 11 junction is indicated by an arrow.
Fig. 2. Mutation screening of the cDNA/ASAH1. Total RNA was isolated from patient's
fibroblasts and reverse-transcribed in cDNA. (A) Agarose gel of amplified full-length
cDNA/ASAH1 showing a 1204 bp fragment in the control sample and a faster migrating
fragment in the patient. (B) Representative region of the electropherogram obtained
after sequence analysis showing the skipping of the full sequences of exons 3 to 5
(c.126_382del). C, Control; FD, Farber patient.
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Direct sequencing revealed a deletion of 9470 bp (g.8728_18197del),
from 3941 nucleotides before the first nucleotide of exon 3 to 1358
nucleotides after the last nucleotide of exon 5 (c.126-3941_382 +
1358del). The exact breakpoint could not be unambiguously ascertained
because of thepresence of an identical nucleotide at both ends. Themost
3′ position (in the sense strand) was used to describe the position of the
breakpoint. The deletion event generated a cleaned junction with no
missing or inserted nucleotides. Large deletions frequently originate
from recombination events promoted by repetitive elements present
in the human genome [33], and breakpoints may also occur at predicted
non-B DNA structures [34]. Therefore, the DNA sequence flanking the
5′ and 3′ deletion breakpoints was screened for the presence of such el-
ements or structures. Analysis with Repeatmasker software revealed no
sequence homology for interspersed repeat elements across or near the
deletion breakpoints. However, these elements are over-represented
in introns 2 to 5 of the gene when compared with the entire gene se-
quence. Sequence analysis with nBMST program identified an inverted
repeat across the 3′ deletion breakpoint and a stretch of 14 dinucleotide
repeats (AC)n located 23 nucleotides upstream of the 3′ breakpoint.
Nevertheless, no significant homology was noticed for the intronic
sequences in the regions flanking the deletion.
3.4. Polymorphic genetic variants
Three documented polymorphisms were found in the FD sample.
Patient's genotype was confirmed by studying parent's sample (data
not shown). The insertion of 29-bp in intron 5 (rs144918941), observed
in a hotspot region of the gene, was transmitted by the mother. The
two single nucleotide polymorphisms c.457 + 45A > G, in intron 6
(rs2073574), and c.737 T > C (p.Val246Ala), in exon 10 (rs10103355),
were observed in homozygosity in all three DNA samples. This infor-
mation may be important in future studies aiming to explore the im-
portance of the backgrounds in which mutations occur.
3.5. Semi-quantitative analysis of the ASAH1 transcript
Analysis of cDNA-PCR products, using GAPDH as endogenous gene
for expression normalization, showed a level reduced to about 50% in
FD cells when compared with the control sample (Fig. 4). This obser-
vation suggests that c.917 + 4A > G is likely to have a negligible im-
pact on the level of the total transcript. This notion is also supported
by the absence of a detectable band corresponding to the full length
cDNA/ASAH1 in FD sample (Fig. 2A). The major abnormal transcript
observed in patient's cells is predicted to code for a shortened poly-
peptide resulting from the deletion of amino acids coded by exons 3
to 5 and the introduction of a premature stop codon due to a frame-
shift abnormality, p.Tyr42_Leu127delinsArgfs*10.
3.6. Analysis of endogenous AC protein
The molecular forms of AC present in total cell lysates from FD,
FD-AC and control fibroblasts were studied using distinct antibodies.
After SDS-PAGE (under reducing conditions, RC) and blotting, a band of
about 14 kDa, corresponding to the α-subunit, was detected with MCA
and SHA antibodies in control and FD-AC cells, but not in patient fibro-
blasts (Fig. 5A). Under the same experimental conditions, a band of
about 40 kDa was seen with PCA and SHA antibodies in control and
FD-AC cells, but not in FD cells (Fig. 5B). This band is likely to represent
the mature glycosylated form of the β-subunit as it disappeared when
samples were analyzed under non-reducing conditions (Fig. 5C) which,
in turn, allowed the detection of an additional band of about 50–55 kDa,
presumably corresponding to the precursor form of the enzyme. As
expected, both bands of 14 kDa and 40 kDa showed a higher intensity
in AC-transduced cells than in control samples. Altogether, these findings
also demonstrate the usefulness of MCA and PCA antibodies in future
Fig. 3. Analysis of exons 3 to 5 deletion at the genomic level. (A) Genomic region encompassing exons 3 to 5 (represented as boxes) of ASAH1 gene. The length of each intron and
exon is indicated in base pairs. Long-range PCR was performed using a forward primer in the beginning of intron 2 and a reverse primer in intron 6 (represented by arrows). (B) The
amplification products were visualized in agarose gel showing a ~11 kb fragment in control and patient samples and a much more intense PCR product of about 1.8 kb in the
patient. (C) Sequencing analysis encompassing the deletion junction c.126-3941_382 + 1358del. M, Molecular weight marker (GeneRuller™ 1 kb DNA ladder); C, control; FD,
Farber patient.
Fig. 4. Semi-quantitative studies of cDNA/ASAH1. Total RNA was reversed transcribed
and used for the amplification of a cDNA region of ASAH1 encompassing exons 8 to
14 (822 bp). For expression normalization, GAPDH was used as endogenous gene and
the RT-PCR exponential phase was considered at 25 cycles for both genes. The volume
corresponding to each electrophoresed sample and the expression level referred to as
the ratio of ASAH1/GAPDH is shown below each lane. ASAH1, acid ceramidase gene; C,
control; FD, Farber patient; GAPDH, glyceraldehyde 3-phosphate dehydrogenase gene;
M, DNA molecular weight marker (GeneRuler™ 100 bp DNA ladder).
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studies aiming at understanding the biological effects of mutations on
protein stability and processing.
3.7. Sphingolipid analysis
Total cell ceramide (Cer) and sphingomyelin (SM) levels were
assessed in human fibroblast lysates and data analyzed in terms of
the ratio value, SM/Cer (Fig. 6). NPD-type B cell lines, which are char-
acterized by the storage of SM due to the deficient enzymatic activity
of acid sphingomyelinase, were also included in this study. In these
cells, in addition to the increased level of total SM, a higher level of
total Cer compared with the average level in control cells was ob-
served. Of note, the average level of the SM to Cer ratio was only
slightly increased when compared to control cells. In the neonatal
FD case the increased level of Cer was confirmed and the level of
SM found in the lower range of control values. The SM/Cer, which
was considerably reduced when compared with control cells, was
corrected by the overexpression of AC. In fibroblasts from a milder
FD case, GM2315, the level of SM approximated that of control cells
and the SM/Cer was about 2-fold higher than in the neonatal FD case.
4. Discussion
In fibroblast cells from the neonatal FD patient, molecular studies
of the ASAH1 gene revealed the presence of two novel heterozygous
loss-of-function mutations: the splicing mutation c.917 + 4A > G
and a large intronic deletion encompassing exons 3 to 5. The transition
in the 5′ss consensus sequence of intron 11 represents the third report
of a splicingmutation in theASAH1 gene (c.457 + 4A > G [18], c.1098 +
1G > T [11] and present study). The secondmutation is the first, and to
our best knowledge the only, gross deletion reported in theASAH1 gene.
Based on data reported herein, FD cases with mutation(s) detected in
only one allele on the analysis of just ASAH1 genomic DNA must be ex-
amined for the presence of a large heterozygous deletion in the second
allele.
The precise ascertainment of the genotype is important for a correct
establishment of genotype-phenotype correlations and, subsequently,
for genetic counseling of patients and families with this specific rare
disease. In this regard, experimental and in silico data analysis presented
in this study clearly demonstrate that these two novel mutations result
in null alleles, thus explaining the disease's clinical severity of this
compound heterozygous FD case. The primary transcript generated by
the allele carrying the splicing mutation is likely to be prematurely de-
graded as no detectable transcripts were seen after cDNA amplification.
For the other allele, the main identified transcript lacked the entire
sequences of exons 3 to 5, predicting the production of a truncated
polypeptide with only 52 amino acids, of which 42 correspond to the
wild-type N-terminal primary sequence of AC. No detectable molecular
forms corresponding to precursor or proteolytically processed mature
protein were observed. Thus, if this aberrant transcript escapes to deg-
radation by thenonsense-mediatedmRNAdecaymechanism [35] and is
translated, then themutant polypeptidemust beprematurely degraded.
Fig. 5. Study of acid ceramidase processing in fibroblasts. Cell lysates were subjected to
SDS-PAGE under reducing (Panels A, B and C-RC) or non-reducing conditions (Panel
C-NRC) followed byWestern blotting as described in Materials and methods. C, Control
cells; FD, Farber cells; FD-AC, AC-transduced FD cells; MCA, anti-human ACmonoclonal
antibody; NRC, non-reducing conditions; PCA, anti-human AC polyclonal antibody; RC,
reducing conditions; SHA, anti-recombinant human AC polyclonal antibody.
Fig. 6. Ceramide and sphingomyelin analysis in fibroblast lysates. Lipids were extracted and quantified as described in Materials and methods. Each assay was performed in dupli-
cate. At least 3 independent determinations were performed for each cell line. Similar values as in control fibroblasts were obtained in pSV40 transformed control cells. Data is
expressed as percent of control mean value ± S.D. Control values (mean ± S.D.) for ceramide, sphingomyelin and SM/CER ratio were 1350 ± 292 pmol/mg, 26900 ±
5859 pmol/mg and 19.4 ± 4.0, respectively. C, Control; CER, ceramide; FD, Farber patient (present case, subtype 4); FD-AC, AC-transduced FD cells (5X- or 10X-infected cells);
GM2315, Farber patient (subtype 3); NPB, Niemann–Pick disease type B; SM, sphingomyelin.
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In compliancewith thesefindings, the in vitro residual enzymatic activ-
ity observed in patient's cells [23] represents one of the lowest values
reported for FD patients [11].
Data described herein strongly support the existence of a deep
blockage of the last step of the sphingolipid (SL) degradation pathway
in patient's cells due to the absence of any functionally active AC. This
fact led us to reanalyze the intracellular level of two structurally close
and metabolically linked SLs, Cer and SM. The ratio value obtained for
the total level of SM vs. Cer was significantly decreased in FD cells,
particularly in the neonatal form, but an analogous disproportion,
i.e. a significant increase, was not seen in NPD-type B cells. Thus, the
imbalance of total SM to total Cer observed in FD fibroblasts is likely
to be due not only to the abnormally high level of Cer but also to a
slightly decreased level of SM. In FD cells the enzymatic activity of
acid sphingomyelinase was normal or decreased, particularly in the
neonatal form (M. Alves, T. Levade and M.G. Ribeiro, unpublished
results). In NPD types A and B, the disruption of the SL catabolic path-
way is located one stepupstreamof that catalyzed by theAC. Altogether,
these findings suggest that a yet unknown balancing mechanism(s) is
altered in NPD-type fibroblasts and, apparently, blocked in FD. In view
of these findings, an accurate assessment of the level of SLs seems to
be helpful in detecting secondary imbalances in the cellular content
and distribution these lipid molecules, including glycosphingolipids,
which might be informative for the disease progression.
In conclusion, data presented herein contribute not only to broaden
the spectrum of disease-causing mutations and enlarge the knowledge
on themolecular mechanisms of FD, but they also challenge a thorough
characterization of diseased cells, as these cellular models might in-
crease our understanding of disease pathophysiology.
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